

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Albumin, g/dL

Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	249	3.80	0.42	11.04	6
Bromcresol Green (BCG) - (Your Method)	252	3.80	0.43	11.24	6
Erba EM 200 - (Your Analyzer)	21	3.59	0.16	4.46	--


Evaluation Based On - All Method Evaluation

Your Result	3.58	SDI / z-Score	0.35
Assigned Value	3.52	Average SDI	0.28
SDPA	0.160	Uncertainty of AV	0.02
Standard Unit Result Val	3.58	%DEV	-0.31


Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4


Frequency Histogram




Z-Score Trend - Within Round



Frequency Histogram Your Method



Frequency Histogram Your Analyzer



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Albumin

		N	Mean	SD	CV%	Excluded
	All Analyzer	249	3.80	0.42	11.04	6
Your Analyzer :	Erba EM 200	21	3.59	0.16	4.46	--
	Fuji Dri-Chem NX500/i	43	4.41	0.31	7.06	1
	Fuji Dri-Chem NX500/i	43	4.41	0.31	7.11	1
	Fuji Dri-Chem NX500/i	43	4.41	0.31	7.11	1
	Roche cobas c 311	29	3.51	0.11	3.02	1
	Roche cobas c 311	29	3.51	0.11	3.02	1
	Roche cobas c 111	19	3.64	0.13	3.60	--
	Fuji Dri-Chem 4000i	16	4.34	0.31	7.24	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, ALP, U/L

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	250	50.49	12.93	25.62	8
PNPP, AMP Buffer - (Your Method)	136	49.81	7.61	15.28	7
Erba EM 200 - (Your Analyzer)	20	49.00	7.53	15.36	1

Evaluation Based On - Method wise Peer Grouping

Your Result	42.00	SDI / z-Score	-0.99
Assigned Value	48.68	Average SDI	-0.71
SDPA	6.755	Uncertainty of AV	0.55
Standard Unit Result Val	42.00	%DEV	-14.29

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, ALP		N	Mean	SD	CV%	Excluded
	All Analyzer	250	50.49	12.93	25.62	8
Your Analyzer :	Erba EM 200	20	49.00	7.53	15.36	1
	Fuji Dri-Chem NX500/i	47	53.00	6.60	12.45	4
	Fuji Dri-Chem NX500/i	47	53.00	6.60	12.45	4
	Fuji Dri-Chem NX500/i	47	53.05	6.59	12.42	4
	Roche cobas c 311	28	47.59	3.76	7.91	--
	Roche cobas c 311	28	47.59	3.76	7.91	--
	Roche cobas c 111	17	48.05	6.99	14.54	--
	Fuji Dri-Chem 4000i	16	50.69	7.50	14.79	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, ALT, U/L



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	249	7.04	2.21	31.40	9
IFCC - UV without P5P - (Your Method)	28	7.09	2.26	31.95	1
Erba EM 200 - (Your Analyzer)	22	5.95	2.26	38.02	2

Your Result	6.80	SDI / z-Score	0.70
Assigned Value	5.66	Average SDI	-0.02
SDPA	1.630	Uncertainty of AV	0.39
Standard Unit Result Val	6.80	%DEV	14.38

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, ALT		N	Mean	SD	CV%	Excluded
	All Analyzer	249	7.04	2.21	31.40	9
Your Analyzer :	Erba EM 200	22	5.95	2.26	38.02	2
	Fuji Dri-Chem NX500/i	41	9.28	0.96	10.35	1
	Fuji Dri-Chem NX500/i	41	9.28	0.96	10.35	1
	Roche cobas c 311	29	6.00	0.85	14.17	--
	Roche cobas c 311	29	6.00	0.85	14.17	--
	Roche cobas c 111	19	4.99	0.76	15.26	1
	Fuji Dri-Chem 4000i	16	8.38	1.09	12.99	--
	Fuji Dri-Chem NX600	15	8.93	1.16	13.02	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, AST, U/L

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	246	13.92	2.85	20.44	4
IFCC - UV without P5P - (Your Method)	29	12.71	1.94	15.28	--
Erba EM 200 - (Your Analyzer)	22	12.97	2.93	22.57	--

Evaluation Based On - All Method Evaluation

Your Result	10.80	SDI / z-Score	-0.79
Assigned Value	12.91	Average SDI	-0.88
SDPA	2.679	Uncertainty of AV	0.61
Standard Unit Result Val	10.80	%DEV	-16.72

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, AST		N	Mean	SD	CV%	Excluded
	All Analyzer	246	13.92	2.85	20.44	4
Your Analyzer :	Erba EM 200	22	12.97	2.93	22.57	--
	Fuji Dri-Chem NX500/i	42	15.93	0.82	5.14	--
	Fuji Dri-Chem NX500/i	42	15.93	0.82	5.14	--
	Fuji Dri-Chem NX500/i	42	15.95	0.82	5.11	--
	Roche cobas c 311	28	11.89	0.98	8.20	--
	Roche cobas c 311	28	11.89	0.98	8.20	--
	Roche cobas c 111	19	11.88	1.01	8.54	--
	Fuji Dri-Chem 4000i	16	15.31	0.79	5.18	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Bilirubin Direct, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	235	0.16	0.11	69.43	8
Diazonium Ion - (Your Method)	10	0.12	0.12	98.37	--
Erba EM 200 - (Your Analyzer)	19	0.07	0.10	131.08	2

Evaluation Based On - Equipment wise Peer Grouping

Your Result	0.02	SDI / z-Score	-1.58
Assigned Value	0.22	Average SDI	-1.18
SDPA	0.125	Uncertainty of AV	0.02
Standard Unit Result Val	0.02	%DEV	-72.97

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Bilirubin Direct		N	Mean	SD	CV%	Excluded
	All Analyzer	235	0.16	0.11	68.13	8
Your Analyzer :	Erba EM 200	19	0.07	0.10	131.08	2
	Fuji Dri-Chem NX500/i	42	0.10	0.03	32.32	--
	Fuji Dri-Chem NX500/i	42	0.10	0.03	28.71	--
	Fuji Dri-Chem NX500/i	42	0.10	0.03	28.71	--
	Roche cobas c 311	28	0.31	0.05	16.03	--
	Roche cobas c 311	28	0.31	0.05	16.03	--
	Roche cobas c 111	19	0.19	0.06	30.48	--
	Fuji Dri-Chem 4000i	15	0.10	0.00	0.00	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Chloride, mEq/L

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	145	132.60	31.04	23.41	12
ISE direct - (Your Method)	96	136.95	33.61	24.54	9
EasyLyte - (Your Analyzer)	11	195.83	25.63	13.09	5

Evaluation Based On - Method wise Peer Grouping

Your Result	248.80	SDI / z-Score	3.55
Assigned Value	133.07	Average SDI	3.47
SDPA	32.631	Uncertainty of AV	4.48
Standard Unit Result Val	248.80	%DEV	27.05

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Chloride

		N	Mean	SD	CV%	Excluded
	All Analyzer	145	132.60	31.04	23.41	12
Your Analyzer :	EasyLyte	11	195.83	25.63	13.09	5
	Roche cobas c 311	20	115.29	10.48	9.09	--
	Roche cobas c 311	20	115.29	10.48	9.09	--
	Roche AVL 9180	15	131.58	23.02	17.50	2
	Fuji Dri-Chem NX500/i	11	156.82	19.31	12.32	--
	Roche cobas 6000	8	112.65	9.18	8.15	--
	Roche cobas 8000	6	122.17	8.81	7.21	--
	VITROS 250	5	89.66	10.02	11.18	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Cholesterol, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	244	131.56	9.93	7.55	4
CHOD-PAP - (Your Method)	58	134.96	8.64	6.40	--
Erba EM 200 - (Your Analyzer)	21	136.17	8.38	6.15	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	126.00	SDI / z-Score	-0.82
Assigned Value	133.92	Average SDI	-0.83
SDPA	9.700	Uncertainty of AV	1.24
Standard Unit Result Val	126.00	%DEV	-7.47

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Cholesterol		N	Mean	SD	CV%	Excluded
	All Analyzer	244	131.56	9.93	7.55	4
Your Analyzer :	Erba EM 200	21	136.17	8.38	6.15	--
	Fuji Dri-Chem NX500/i	42	121.43	7.26	5.98	--
	Fuji Dri-Chem NX500/i	42	121.48	7.26	5.98	--
	Fuji Dri-Chem NX500/i	42	121.48	7.26	5.98	--
	Roche cobas c 311	29	136.43	3.82	2.80	--
	Roche cobas c 311	29	136.43	3.82	2.80	--
	Roche cobas c 111	19	137.25	5.79	4.22	1
	Fuji Dri-Chem 4000i	16	121.75	10.12	8.31	1

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Creatinine, mg/dl

Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	245	0.74	0.09	12.36	5
Enzymatic - (Your Method)	28	0.76	0.11	14.85	--
Erba EM 200 - (Your Analyzer)	20	0.77	0.12	15.16	--


Evaluation Based On - All Method Evaluation

Your Result	0.86	SDI / z-Score	0.70
Assigned Value	0.77	Average SDI	0.67
SDPA	0.126	Uncertainty of AV	0.03
Standard Unit Result Val	0.86	%DEV	12.42


Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4


Frequency Histogram




Z-Score Trend - Within Round



Frequency Histogram Your Method



Frequency Histogram Your Analyzer



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Creatinine		N	Mean	SD	CV%	Excluded
	All Analyzer	245	0.74	0.09	12.36	5
Your Analyzer :	Erba EM 200	20	0.77	0.12	15.16	--
	Fuji Dri-Chem NX500/i	42	0.70	0.05	7.13	1
	Fuji Dri-Chem NX500/i	42	0.70	0.05	7.10	1
	Fuji Dri-Chem NX500/i	42	0.70	0.05	7.10	1
	Roche cobas c 311	29	0.72	0.05	7.08	--
	Roche cobas c 311	29	0.72	0.05	7.08	--
	Roche cobas c 111	18	0.73	0.08	11.19	--
	Fuji Dri-Chem 4000i	17	0.70	0.05	6.88	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Glucose, mg/dl

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	244	67.60	7.34	10.85	3
Glucose oxidase, hydrogen peroxide (Trinder) - (Your Metho	102	64.67	8.45	13.07	1
Erba EM 200 - (Your Analyzer)	21	77.41	5.13	6.63	1

Evaluation Based On - All Method Evaluation

Your Result	84.20	SDI / z-Score	1.37
Assigned Value	76.47	Average SDI	1.40
SDPA	5.635	Uncertainty of AV	1.23
Standard Unit Result Val	84.20	%DEV	8.78

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Glucose

		N	Mean	SD	CV%	Excluded
	All Analyzer	244	67.60	7.34	10.85	3
Your Analyzer :	Erba EM 200	21	77.41	5.13	6.63	1
	Fuji Dri-Chem NX500/i	40	58.78	3.56	6.05	--
	Fuji Dri-Chem NX500/i	40	58.82	3.54	6.01	--
	Fuji Dri-Chem NX500/i	40	58.82	3.54	6.01	--
	Roche cobas c 311	29	68.86	2.01	2.93	1
	Roche cobas c 311	29	68.86	2.01	2.93	1
	Roche cobas c 111	18	71.11	2.94	4.14	--
	Fuji Dri-Chem 4000i	17	58.59	3.28	5.60	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, HDL, mg/dl

Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	232	31.23	3.22	10.32	4
Direct measure-PEG - (Your Method)	32	31.90	3.37	10.55	2
Erba EM 200 - (Your Analyzer)	20	33.20	2.90	8.74	1


Evaluation Based On - All Method Evaluation

Your Result	34.90	SDI / z-Score	0.53
Assigned Value	33.02	Average SDI	0.60
SDPA	3.532	Uncertainty of AV	0.59
Standard Unit Result Val	34.90	%DEV	5.14


Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4


Frequency Histogram




Z-Score Trend - Within Round



Frequency Histogram Your Method



Frequency Histogram Your Analyzer



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, HDL		N	Mean	SD	CV%	Excluded
	All Analyzer	232	31.23	3.22	10.32	4
Your Analyzer :	Erba EM 200	20	33.20	2.90	8.74	1
	Fuji Dri-Chem NX500/i	41	30.76	2.39	7.76	--
	Fuji Dri-Chem NX500/i	41	30.79	2.38	7.74	--
	Fuji Dri-Chem NX500/i	41	30.79	2.38	7.74	--
	Roche cobas c 311	29	29.01	1.52	5.22	--
	Roche cobas c 311	29	29.01	1.52	5.22	--
	Roche cobas c 111	18	29.69	1.36	4.58	--
	Fuji Dri-Chem 4000i	15	31.40	1.84	5.87	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Potassium, mEq/L

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	220	3.68	0.16	4.27	1
ISE direct - (Your Method)	169	3.67	0.17	4.50	--
EasyLyte - (Your Analyzer)	14	3.67	0.20	5.36	--

Evaluation Based On - Method wise Peer Grouping

Your Result	3.59	SDI / z-Score	-0.27
Assigned Value	3.66	Average SDI	-0.07
SDPA	0.240	Uncertainty of AV	0.01
Standard Unit Result Val	3.59	%DEV	-2.29

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Potassium		N	Mean	SD	CV%	Excluded
	All Analyzer	220	3.68	0.16	4.27	1
Your Analyzer :	EasyLyte	14	3.67	0.20	5.36	--
	Fuji Dri-Chem NX500/i	45	3.65	0.13	3.43	--
	Fuji Dri-Chem NX500/i	45	3.65	0.13	3.43	--
	Fuji Dri-Chem NX500/i	45	3.65	0.13	3.43	--
	Roche cobas c 311	21	3.77	0.15	3.88	--
	Roche cobas c 311	21	3.77	0.15	3.88	--
	Fuji Dri-Chem 4000i	20	3.65	0.13	3.62	--
	Roche AVL 9180	19	3.81	0.19	4.96	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Sodium, mEq/L

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	219	138.19	4.12	2.98	3
ISE direct - (Your Method)	168	137.99	4.35	3.15	2
EasyLyte - (Your Analyzer)	14	138.17	3.71	2.68	--

Evaluation Based On - Method wise Peer Grouping

Your Result	133.90	SDI / z-Score	-0.52
Assigned Value	137.45	Average SDI	-0.31
SDPA	6.800	Uncertainty of AV	0.29
Standard Unit Result Val	133.90	%DEV	-3.09

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Sodium		N	Mean	SD	CV%	Excluded
	All Analyzer	219	138.19	4.12	2.98	3
Your Analyzer :	EasyLyte	14	138.17	3.71	2.68	--
	Fuji Dri-Chem NX500/i	46	137.78	4.45	3.23	--
	Fuji Dri-Chem NX500/i	46	137.78	4.45	3.23	--
	Fuji Dri-Chem NX500/i	46	137.80	4.45	3.23	--
	Roche cobas c 311	20	138.70	3.20	2.31	--
	Roche cobas c 311	20	138.70	3.20	2.31	--
	Fuji Dri-Chem 4000i	19	138.28	3.18	2.30	1
	Roche AVL 9180	18	137.02	3.90	2.85	1

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Total Protein, g/dL



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	241	6.01	0.34	5.66	2
Biuret - (Your Method)	237	6.02	0.34	5.71	2
Erba EM 200 - (Your Analyzer)	22	6.31	0.32	5.09	--

Your Result	6.32	SDI / z-Score	0.16
Assigned Value	6.26	Average SDI	0.28
SDPA	0.385	Uncertainty of AV	0.08
Standard Unit Result Val	6.32	%DEV	0.19

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Total Protein		N	Mean	SD	CV%	Excluded
	All Analyzer	241	6.01	0.34	5.66	2
Your Analyzer :	Erba EM 200	22	6.31	0.32	5.09	--
	Fuji Dri-Chem NX500/i	41	6.20	0.27	4.34	2
	Fuji Dri-Chem NX500/i	41	6.20	0.27	4.34	2
	Roche cobas c 311	29	5.90	0.16	2.75	--
	Roche cobas c 311	29	5.90	0.16	2.75	--
	Roche cobas c 111	17	5.92	0.26	4.41	--
	Fuji Dri-Chem 4000i	16	6.01	0.32	5.35	--
	Fuji Dri-Chem NX600	14	5.98	0.18	3.03	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Triglycerides, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	239	121.75	9.66	7.93	2
GPO-PAP - (Your Method)	30	119.00	10.21	8.58	--
Erba EM 200 - (Your Analyzer)	20	107.99	7.50	6.94	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	107.30	SDI / z-Score	-0.12
Assigned Value	108.82	Average SDI	-0.07
SDPA	12.500	Uncertainty of AV	2.02
Standard Unit Result Val	107.30	%DEV	-0.64

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Triglycerides

		N	Mean	SD	CV%	Excluded
	All Analyzer	239	121.75	9.66	7.93	2
Your Analyzer :	Erba EM 200	20	107.99	7.50	6.94	--
	Fuji Dri-Chem NX500/i	40	127.69	7.85	6.15	--
	Fuji Dri-Chem NX500/i	40	127.69	7.85	6.15	--
	Fuji Dri-Chem NX500/i	40	127.75	7.86	6.15	--
	Roche cobas c 311	29	123.73	5.28	4.27	--
	Roche cobas c 311	29	123.73	5.28	4.27	--
	Roche cobas c 111	18	126.49	6.12	4.84	1
	Fuji Dri-Chem 4000i	15	124.27	8.57	6.90	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Urea, mg/dl



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	244	19.42	2.12	10.89	6
Urease GLDH, UV - (Your Method)	8	19.88	3.87	19.48	--
Erba EM 200 - (Your Analyzer)	22	20.28	2.98	14.67	--

Your Result	20.30	SDI / z-Score	0.02
Assigned Value	20.26	Average SDI	-0.12
SDPA	2.828	Uncertainty of AV	0.62
Standard Unit Result Val	20.30	%DEV	0.10

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Urea		N	Mean	SD	CV%	Excluded
	All Analyzer	244	19.42	2.12	10.89	6
Your Analyzer :	Erba EM 200	22	20.28	2.98	14.67	--
	Fuji Dri-Chem NX500/i	40	19.68	1.21	6.15	4
	Fuji Dri-Chem NX500/i	40	19.70	1.22	6.19	4
	Fuji Dri-Chem NX500/i	40	19.70	1.22	6.19	4
	Roche cobas c 311	29	19.39	0.88	4.55	--
	Roche cobas c 311	29	19.39	0.88	4.55	--
	Roche cobas c 111	18	18.28	1.36	7.46	--
	Fuji Dri-Chem 4000i	16	19.48	1.17	5.99	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Uric Acid, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	241	4.17	0.45	10.79	4
Uricase, UV - (Your Method)	28	4.34	0.65	14.96	2
Erba EM 200 - (Your Analyzer)	19	4.76	0.32	6.74	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	5.00	SDI / z-Score	0.51
Assigned Value	4.74	Average SDI	0.82
SDPA	0.510	Uncertainty of AV	0.09
Standard Unit Result Val	5.00	%DEV	4.98

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 1

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Uric Acid

	N	Mean	SD	CV%	Excluded
All Analyzer	241	4.17	0.45	10.79	4
Your Analyzer : Erba EM 200	19	4.76	0.32	6.74	--
Fuji Dri-Chem NX500/i	40	4.16	0.25	6.06	1
Fuji Dri-Chem NX500/i	40	4.16	0.25	6.06	1
Fuji Dri-Chem NX500/i	40	4.16	0.25	6.06	1
Roche cobas c 311	27	3.91	0.12	3.12	--
Roche cobas c 311	27	3.91	0.12	3.12	--
Fuji Dri-Chem 4000i	19	4.18	0.20	4.88	1
Roche cobas c 111	18	3.89	0.21	5.32	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error

Dr Puneet Kumar Nigam

Dr Puneet Kumar Nigam
PT coordinator & Technical Manager, MHL EQAS
Unit No. 409-416,
Commercial Building - 1A,
Kohinoor Mall, Kirol Road, Kurla (W),
Mumbai - 400070



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022



Biochemistry, Albumin, g/dL

Comparative Statistics	N	Mean	SD	CV%	Excluded
All Methods	249	3.77	0.45	11.85	3
Bromcresol Green (BCG) - (Your Method)	247	3.77	0.45	11.85	3
Erba EM 200 - (Your Analyzer)	21	3.58	0.17	4.77	--

Your Result	3.65	SDI / z-Score	0.22
Assigned Value	3.58	Average SDI	0.28
SDPA	0.340	Uncertainty of AV	0.04
Standard Unit Result Val	3.65	%DEV	1.90

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Albumin

		N	Mean	SD	CV%	Excluded
	All Analyzer	249	3.77	0.45	11.85	3
Your Analyzer :	Erba EM 200	21	3.58	0.17	4.77	--
	Fuji Dri-Chem NX500/i	45	4.33	0.38	8.79	1
	Fuji Dri-Chem NX500/i	42	4.34	0.39	8.92	1
	Fuji Dri-Chem NX500/i	42	4.35	0.38	8.76	1
	Fuji Dri-Chem NX500/i	41	4.35	0.39	8.87	1
	Roche cobas c 311	28	3.46	0.19	5.35	--
	Roche cobas c 311	27	3.47	0.18	5.25	--
	Roche cobas c 111	19	3.59	0.19	5.30	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, ALP, U/L

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	250	49.92	12.27	24.59	5
PNPP, AMP Buffer - (Your Method)	133	49.87	9.33	18.71	4
Erba EM 200 - (Your Analyzer)	20	52.90	9.79	18.50	1

Evaluation Based On - Method wise Peer Grouping

Your Result	44.00	SDI / z-Score	-0.42
Assigned Value	48.71	Average SDI	-0.71
SDPA	11.300	Uncertainty of AV	0.62
Standard Unit Result Val	44.00	%DEV	-16.82

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, ALP		N	Mean	SD	CV%	Excluded
	All Analyzer	250	49.92	12.27	24.59	5
Your Analyzer :	Erba EM 200	20	52.90	9.79	18.50	1
	Fuji Dri-Chem NX500/i	49	53.26	7.21	13.53	3
	Fuji Dri-Chem NX500/i	46	53.35	7.45	13.97	3
	Fuji Dri-Chem NX500/i	46	53.74	6.88	12.81	3
	Fuji Dri-Chem NX500/i	45	53.79	6.96	12.94	3
	Roche cobas c 311	27	46.15	3.82	8.28	--
	Roche cobas c 311	26	46.23	3.87	8.37	--
	Roche cobas c 111	17	47.34	6.60	13.94	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, AST, U/L



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	246	13.96	3.07	21.97	6
IFCC - UV without P5P - (Your Method)	28	12.63	1.74	13.78	1
Erba EM 200 - (Your Analyzer)	22	13.64	2.47	18.08	1

Your Result	9.90	SDI / z-Score	-1.20
Assigned Value	13.33	Average SDI	-0.88
SDPA	2.858	Uncertainty of AV	0.65
Standard Unit Result Val	9.90	%DEV	-27.44

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, AST		N	Mean	SD	CV%	Excluded
All Analyzer		246	13.96	3.07	21.97	6
Your Analyzer :	Erba EM 200	22	13.64	2.47	18.08	1
	Fuji Dri-Chem NX500/i	45	15.98	1.01	6.33	--
	Fuji Dri-Chem NX500/i	42	15.98	1.05	6.55	--
	Fuji Dri-Chem NX500/i	42	16.05	0.94	5.83	--
	Fuji Dri-Chem NX500/i	41	16.05	0.95	5.90	--
	Roche cobas c 311	27	11.75	1.47	12.50	--
	Roche cobas c 311	26	11.84	1.40	11.86	--
	Roche cobas c 111	19	11.58	1.26	10.85	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Bilirubin Direct, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	235	0.17	0.12	72.94	12
Diazonium Ion - (Your Method)	10	0.15	0.13	85.62	--
Erba EM 200 - (Your Analyzer)	19	0.12	0.14	118.97	3

Evaluation Based On - Equipment wise Peer Grouping

Your Result	0.02	SDI / z-Score	-2.32
Assigned Value	0.23	Average SDI	-1.18
SDPA	0.090	Uncertainty of AV	0.01
Standard Unit Result Val	0.02	%DEV	-82.76

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Bilirubin Direct		N	Mean	SD	CV%	Excluded
	All Analyzer	235	0.18	0.12	70.29	12
Your Analyzer :	Erba EM 200	19	0.12	0.14	118.97	3
	Fuji Dri-Chem NX500/i	43	0.10	0.03	34.38	--
	Fuji Dri-Chem NX500/i	40	0.10	0.03	27.00	--
	Fuji Dri-Chem NX500/i	40	0.10	0.02	22.55	--
	Fuji Dri-Chem NX500/i	39	0.10	0.02	23.53	--
	Roche cobas c 311	27	0.36	0.07	18.49	--
	Roche cobas c 311	26	0.36	0.07	18.59	--
	Roche cobas c 111	19	0.20	0.06	30.20	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Chloride, mEq/L

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	145	134.73	34.01	25.24	9
ISE direct - (Your Method)	97	140.24	36.69	26.16	6
EasyLyte - (Your Analyzer)	11	199.59	35.80	17.94	3

Evaluation Based On - Method wise Peer Grouping

Your Result	248.70	SDI / z-Score	3.40
Assigned Value	134.13	Average SDI	3.47
SDPA	33.717	Uncertainty of AV	4.57
Standard Unit Result Val	248.70	%DEV	24.61

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Chloride		N	Mean	SD	CV%	Excluded
	All Analyzer	145	134.73	34.01	25.24	9
Your Analyzer :	EasyLyte	11	199.59	35.80	17.94	3
	Roche cobas c 311	19	113.51	11.88	10.47	--
	Roche cobas c 311	18	114.32	11.68	10.22	--
	Roche AVL 9180	16	134.49	27.92	20.76	2
	Fuji Dri-Chem NX500/i	12	154.50	17.27	11.18	--
	Roche cobas 6000	8	112.49	7.80	6.94	--
	Roche cobas 8000	6	122.20	8.84	7.23	--
	VITROS 250	5	104.00	32.06	30.82	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Cholesterol, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	244	131.73	10.86	8.25	4
CHOD-PAP - (Your Method)	56	135.07	8.89	6.58	2
Erba EM 200 - (Your Analyzer)	21	135.45	8.17	6.03	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	127.00	SDI / z-Score	-0.84
Assigned Value	134.13	Average SDI	-0.83
SDPA	8.490	Uncertainty of AV	1.70
Standard Unit Result Val	127.00	%DEV	-6.24

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Cholesterol

		N	Mean	SD	CV%	Excluded
	All Analyzer	244	131.73	10.86	8.25	4
Your Analyzer :	Erba EM 200	21	135.45	8.17	6.03	--
	Fuji Dri-Chem NX500/i	44	122.81	9.28	7.56	--
	Fuji Dri-Chem NX500/i	41	122.21	9.36	7.66	--
	Fuji Dri-Chem NX500/i	41	122.42	9.33	7.62	--
	Fuji Dri-Chem NX500/i	40	122.21	9.36	7.66	--
	Roche cobas c 311	28	135.71	5.76	4.24	--
	Roche cobas c 311	27	135.77	5.86	4.32	--
	Roche cobas c 111	19	137.39	9.78	7.12	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Creatinine, mg/dl


Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	245	0.72	0.11	15.08	4
Enzymatic - (Your Method)	28	0.72	0.14	19.19	--
Erba EM 200 - (Your Analyzer)	20	0.71	0.16	23.07	--

Your Result	0.86	SDI / z-Score	0.64
Assigned Value	0.76	Average SDI	0.67
SDPA	0.160	Uncertainty of AV	0.04
Standard Unit Result Val	0.86	%DEV	20.96

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Creatinine		N	Mean	SD	CV%	Excluded
	All Analyzer	245	0.72	0.11	15.08	4
Your Analyzer :	Erba EM 200	20	0.71	0.16	23.07	--
	Fuji Dri-Chem NX500/i	44	0.67	0.07	9.81	1
	Fuji Dri-Chem NX500/i	41	0.67	0.07	10.13	1
	Fuji Dri-Chem NX500/i	41	0.68	0.06	9.48	1
	Fuji Dri-Chem NX500/i	40	0.67	0.06	9.50	1
	Roche cobas c 311	28	0.69	0.05	7.43	--
	Roche cobas c 311	27	0.69	0.05	7.41	--
	Roche cobas c 111	18	0.71	0.07	9.45	1

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Glucose, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	244	65.74	7.49	11.39	6
Glucose oxidase, hydrogen peroxide (Trinder) - (Your Metho	101	62.94	8.56	13.60	4
Erba EM 200 - (Your Analyzer)	21	75.48	4.67	6.19	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	83.60	SDI / z-Score	1.42
Assigned Value	74.76	Average SDI	1.40
SDPA	6.241	Uncertainty of AV	1.38
Standard Unit Result Val	83.60	%DEV	10.76

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Glucose		N	Mean	SD	CV%	Excluded
	All Analyzer	244	65.74	7.49	11.39	6
Your Analyzer :	Erba EM 200	21	75.48	4.67	6.19	--
	Fuji Dri-Chem NX500/i	42	57.48	4.06	7.06	--
	Fuji Dri-Chem NX500/i	39	57.42	4.21	7.34	--
	Fuji Dri-Chem NX500/i	39	57.61	4.07	7.07	--
	Fuji Dri-Chem NX500/i	38	57.59	4.13	7.17	--
	Roche cobas c 311	28	66.04	2.98	4.51	1
	Roche cobas c 311	27	66.04	3.04	4.60	1
	Roche cobas c 111	18	68.15	3.93	5.77	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, HDL, mg/dl



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	232	30.90	3.50	11.32	3
Direct measure-PEG - (Your Method)	31	31.52	3.86	12.25	1
Erba EM 200 - (Your Analyzer)	20	33.49	2.94	8.78	1

Your Result	35.20	SDI / z-Score	0.66
Assigned Value	32.59	Average SDI	0.60
SDPA	3.955	Uncertainty of AV	0.65
Standard Unit Result Val	35.20	%DEV	5.12

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, HDL		N	Mean	SD	CV%	Excluded
	All Analyzer	232	30.90	3.50	11.32	3
Your Analyzer :	Erba EM 200	20	33.49	2.94	8.78	1
	Fuji Dri-Chem NX500/i	43	30.72	2.34	7.60	--
	Fuji Dri-Chem NX500/i	40	30.47	2.23	7.30	--
	Fuji Dri-Chem NX500/i	40	30.56	2.27	7.42	--
	Fuji Dri-Chem NX500/i	39	30.47	2.23	7.30	--
	Roche cobas c 311	28	27.96	1.59	5.67	--
	Roche cobas c 311	27	27.96	1.62	5.78	--
	Roche cobas c 111	18	28.57	1.53	5.35	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Potassium, mEq/L

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	219	3.63	0.19	5.34	4
ISE direct - (Your Method)	167	3.61	0.19	5.34	2
EasyLyte - (Your Analyzer)	14	3.60	0.23	6.31	--

Evaluation Based On - Method wise Peer Grouping

Your Result	3.64	SDI / z-Score	0.14
Assigned Value	3.61	Average SDI	-0.07
SDPA	0.206	Uncertainty of AV	0.02
Standard Unit Result Val	3.64	%DEV	1.22

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Potassium		N	Mean	SD	CV%	Excluded
All Analyzer		219	3.63	0.19	5.34	4
Your Analyzer :	EasyLyte	14	3.60	0.23	6.31	--
	Fuji Dri-Chem NX500/i	46	3.61	0.20	5.65	1
	Fuji Dri-Chem NX500/i	43	3.59	0.20	5.43	1
	Fuji Dri-Chem NX500/i	43	3.60	0.20	5.59	1
	Fuji Dri-Chem NX500/i	42	3.59	0.20	5.52	1
	Fuji Dri-Chem 4000i	20	3.58	0.20	5.67	--
	Roche AVL 9180	20	3.72	0.17	4.57	--
	Roche cobas c 311	20	3.74	0.19	4.98	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Sodium, mEq/L

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	217	137.35	5.42	3.95	2
ISE direct - (Your Method)	165	137.01	5.60	4.09	1
EasyLyte - (Your Analyzer)	14	136.40	5.60	4.11	--

Evaluation Based On - Method wise Peer Grouping

Your Result	136.20	SDI / z-Score	-0.10
Assigned Value	136.80	Average SDI	-0.31
SDPA	6.200	Uncertainty of AV	0.55
Standard Unit Result Val	136.20	%DEV	-0.15

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Sodium		N	Mean	SD	CV%	Excluded
	All Analyzer	217	137.35	5.42	3.95	2
Your Analyzer :	EasyLyte	14	136.40	5.60	4.11	--
	Fuji Dri-Chem NX500/i	47	137.70	5.54	4.02	--
	Fuji Dri-Chem NX500/i	44	137.07	5.13	3.75	--
	Fuji Dri-Chem NX500/i	44	137.32	5.34	3.89	--
	Fuji Dri-Chem NX500/i	43	137.09	5.19	3.79	--
	Roche AVL 9180	19	135.89	6.19	4.56	1
	Roche cobas c 311	19	138.00	4.98	3.61	--
	Fuji Dri-Chem 4000i	18	136.17	6.74	4.95	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Total Protein, g/dL



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	242	6.02	0.42	6.97	4
Biuret - (Your Method)	234	6.02	0.42	6.96	4
Erba EM 200 - (Your Analyzer)	22	6.35	0.47	7.35	--

Your Result	6.52	SDI / z-Score	0.39
Assigned Value	6.32	Average SDI	0.28
SDPA	0.520	Uncertainty of AV	0.11
Standard Unit Result Val	6.52	%DEV	2.68

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Total Protein		N	Mean	SD	CV%	Excluded
All Analyzer		242	6.02	0.42	6.97	4
Your Analyzer :	Erba EM 200	22	6.35	0.47	7.35	--
	Fuji Dri-Chem NX500/i	43	6.21	0.35	5.60	2
	Fuji Dri-Chem NX500/i	40	6.17	0.33	5.37	2
	Fuji Dri-Chem NX500/i	40	6.18	0.34	5.45	2
	Fuji Dri-Chem NX500/i	39	6.17	0.33	5.37	2
	Roche cobas c 311	28	5.80	0.27	4.67	--
	Roche cobas c 311	27	5.81	0.27	4.63	--
	Roche cobas c 111	17	5.84	0.30	5.19	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Triglycerides, mg/dl

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	239	129.91	11.35	8.74	5
GPO-PAP - (Your Method)	29	120.74	8.30	6.88	3
Erba EM 200 - (Your Analyzer)	20	117.50	10.74	9.14	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	117.90	SDI / z-Score	-0.02
Assigned Value	118.08	Average SDI	-0.07
SDPA	11.902	Uncertainty of AV	2.76
Standard Unit Result Val	117.90	%DEV	0.34

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Triglycerides

		N	Mean	SD	CV%	Excluded
	All Analyzer	239	129.91	11.35	8.74	5
Your Analyzer :	Erba EM 200	20	117.50	10.74	9.14	--
	Fuji Dri-Chem NX500/i	42	138.00	10.19	7.38	--
	Fuji Dri-Chem NX500/i	39	137.31	10.26	7.47	--
	Fuji Dri-Chem NX500/i	39	137.93	10.09	7.32	--
	Fuji Dri-Chem NX500/i	38	137.69	10.12	7.35	--
	Roche cobas c 311	28	129.08	6.81	5.28	--
	Roche cobas c 311	27	129.90	5.34	4.11	--
	Roche cobas c 111	18	132.87	7.05	5.30	2

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Urea, mg/dl



Comparative Statistics

	N	Mean	SD	CV%	Excluded
All Methods	244	19.33	1.96	10.15	13
Urease GLDH, UV - (Your Method)	8	19.58	1.28	6.51	1
Erba EM 200 - (Your Analyzer)	22	19.74	1.80	9.11	3

Your Result	19.50	SDI / z-Score	-0.26
Assigned Value	20.06	Average SDI	-0.12
SDPA	2.194	Uncertainty of AV	0.50
Standard Unit Result Val	19.50	%DEV	-1.21

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Urea		N	Mean	SD	CV%	Excluded
	All Analyzer	244	19.33	1.96	10.15	13
Your Analyzer :	Erba EM 200	22	19.74	1.80	9.11	3
	Fuji Dri-Chem NX500/i	42	19.62	1.17	5.97	4
	Fuji Dri-Chem NX500/i	39	19.48	1.12	5.75	4
	Fuji Dri-Chem NX500/i	39	19.53	1.14	5.84	4
	Fuji Dri-Chem NX500/i	38	19.48	1.12	5.75	4
	Roche cobas c 311	28	18.99	1.46	7.69	--
	Roche cobas c 311	27	19.06	1.43	7.52	--
	Roche cobas c 111	18	17.89	1.35	7.55	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Uric Acid, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	240	4.06	0.47	11.53	2
Uricase, UV - (Your Method)	28	4.25	0.62	14.53	1
Erba EM 200 - (Your Analyzer)	19	4.67	0.36	7.69	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	5.10	SDI / z-Score	1.13
Assigned Value	4.60	Average SDI	0.82
SDPA	0.442	Uncertainty of AV	0.10
Standard Unit Result Val	5.10	%DEV	9.25

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 2

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Uric Acid

	N	Mean	SD	CV%	Excluded
All Analyzer	240	4.06	0.47	11.53	2
Your Analyzer : Erba EM 200	19	4.67	0.36	7.69	--
Fuji Dri-Chem NX500/i	42	4.07	0.24	5.94	--
Fuji Dri-Chem NX500/i	39	4.06	0.25	6.13	--
Fuji Dri-Chem NX500/i	39	4.07	0.25	6.08	--
Fuji Dri-Chem NX500/i	38	4.06	0.25	6.13	--
Roche cobas c 311	26	3.75	0.19	4.98	--
Roche cobas c 311	25	3.76	0.18	4.86	--
Fuji Dri-Chem 4000i	19	4.03	0.29	7.07	1

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error

Dr Puneet Kumar Nigam

Dr Puneet Kumar Nigam
PT coordinator & Technical Manager, MHL EQAS
Unit No. 409-416,
Commercial Building - 1A,
Kohinoor Mall, Kirol Road, Kurla (W),
Mumbai - 400070



Analyte Methodwise Result Report

Lab : 596
Lab Name : HEALTH HORIZON DIAGNOSTICS
Report Date : 25/01/2023

Cycle No : 220412
Sample No : 3
Sample Date : 27-12-2022



Biochemistry, ALT, U/L

Comparative Statistics	N	Mean	SD	CV%	Excluded
All Methods	238	37.54	3.80	10.12	10
IFCC - UV without P5P - (Your Method)	24	37.94	2.59	6.83	1
Erba EM 200 - (Your Analyzer)	20	37.69	3.62	9.61	1

Your Result	34.80	SDI / z-Score	-0.74
Assigned Value	37.38	Average SDI	-0.02
SDPA	3.509	Uncertainty of AV	0.84
Standard Unit Result Val	34.80	%DEV	-7.67

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, ALT		N	Mean	SD	CV%	Excluded
	All Analyzer	238	37.54	3.80	10.12	10
Your Analyzer :	Erba EM 200	20	37.69	3.62	9.61	1
	Fuji Dri-Chem NX500/i	45	40.28	4.15	10.31	5
	Fuji Dri-Chem NX500/i	44	40.43	4.11	10.17	5
	Fuji Dri-Chem NX500/i	43	40.58	4.06	10.00	5
	Fuji Dri-Chem NX500/i	43	40.58	4.06	10.00	5
	Roche cobas c 311	26	35.62	1.68	4.73	--
	Roche cobas c 311	26	35.62	1.68	4.73	--
	Roche cobas c 111	18	34.16	1.81	5.29	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, AST, U/L

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	234	44.76	5.19	11.59	10
IFCC - UV without P5P - (Your Method)	25	45.78	4.18	9.13	1
Erba EM 200 - (Your Analyzer)	20	49.65	6.79	13.68	2

Evaluation Based On - Equipment wise Peer Grouping

Your Result	43.50	SDI / z-Score	-0.65
Assigned Value	47.71	Average SDI	-0.88
SDPA	6.500	Uncertainty of AV	1.23
Standard Unit Result Val	43.50	%DEV	-12.39

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, AST

		N	Mean	SD	CV%	Excluded
	All Analyzer	234	44.76	5.19	11.59	10
Your Analyzer :	Erba EM 200	20	49.65	6.79	13.68	2
	Fuji Dri-Chem NX500/i	45	44.84	4.86	10.85	4
	Fuji Dri-Chem NX500/i	44	44.59	4.67	10.47	4
	Fuji Dri-Chem NX500/i	43	44.32	4.44	10.02	4
	Fuji Dri-Chem NX500/i	43	44.32	4.44	10.02	4
	Roche cobas c 311	26	41.97	1.83	4.35	--
	Roche cobas c 311	26	41.97	1.83	4.35	--
	Roche cobas c 111	18	45.08	3.48	7.73	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Bilirubin Direct, mg/dl

Comparative Statistics



	N	Mean	SD	CV%	Excluded
All Methods	234	0.21	0.09	41.04	11
Diazonium Ion - (Your Method)	11	0.20	0.12	58.33	1
Erba EM 200 - (Your Analyzer)	19	0.18	0.05	26.55	1

Evaluation Based On - Equipment wise Peer Grouping

Your Result	0.21	SDI / z-Score	0.36
Assigned Value	0.18	Average SDI	-1.18
SDPA	0.075	Uncertainty of AV	0.01
Standard Unit Result Val	0.21	%DEV	18.64

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Bilirubin Direct		N	Mean	SD	CV%	Excluded
	All Analyzer	234	0.21	0.09	40.65	11
Your Analyzer :	Erba EM 200	19	0.18	0.05	26.55	1
	Fuji Dri-Chem NX500/i	44	0.20	0.09	43.00	3
	Fuji Dri-Chem NX500/i	43	0.20	0.09	43.28	3
	Fuji Dri-Chem NX500/i	42	0.20	0.09	43.35	3
	Fuji Dri-Chem NX500/i	42	0.20	0.09	43.35	3
	Roche cobas c 311	26	0.21	0.06	27.23	--
	Roche cobas c 311	26	0.21	0.06	27.23	--
	Roche cobas c 111	18	0.22	0.07	29.02	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error



Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412

Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Biochemistry, Bilirubin Total, mg/dl

Comparative Statistics


	N	Mean	SD	CV%	Excluded
All Methods	235	0.54	0.19	35.24	1
Diazonium Ion - (Your Method)	44	0.66	0.20	30.20	1
Erba EM 200 - (Your Analyzer)	17	0.43	0.10	23.15	--

Evaluation Based On - Equipment wise Peer Grouping

Your Result	0.48	SDI / z-Score	0.38
Assigned Value	0.42	Average SDI	0.38
SDPA	0.160	Uncertainty of AV	0.02
Standard Unit Result Val	0.48	%DEV	11.11

Note : # - Not evaluated / Bimodal distribution

X : SDI more than 4



PC-1022

Analyte Methodwise Result Report

Lab : 596

Cycle No : 220412


Lab Name : HEALTH HORIZON DIAGNOSTICS

Sample No : 3

Report Date : 25/01/2023

Sample Date : 27-12-2022

Absolute Z-Score Average - Across Rounds



Note : SDI with * marked are not considered for evaluation.

Comments :

Biochemistry, Bilirubin Total

		N	Mean	SD	CV%	Excluded
	All Analyzer	235	0.54	0.19	35.24	1
Your Analyzer :	Erba EM 200	17	0.43	0.10	23.15	--
	Fuji Dri-Chem NX500/i	45	0.71	0.17	23.24	1
	Fuji Dri-Chem NX500/i	44	0.71	0.17	23.55	1
	Fuji Dri-Chem NX500/i	43	0.71	0.17	23.73	1
	Fuji Dri-Chem NX500/i	43	0.71	0.17	23.73	1
	Roche cobas c 311	28	0.40	0.08	21.05	--
	Roche cobas c 311	28	0.40	0.08	21.05	--
	Roche cobas c 111	17	0.39	0.09	23.98	--

Remarks: Interpretation of your reports

- a) If your SDI lies between +/- 2.0 SDI then your results are well within limits.
- b) If your SDI lies between +/-2.0 to 2.99 SDI then it is a warning alert flag.
- c) If your SDI is +/- 3.0 SDI or more then it is an action alert flag.

Interpretation when an analyte is reported for multiple samples in a Round:

- a) Reported on 2 samples:
 - Two out of two pass - Acceptable performance
 - One out of two pass - Review for random error & take action if appropriate
 - Both failed - Unacceptable performance, Review for systematic error
- b) Reported on 3 samples:
 - All pass - Acceptable performance
 - Two out of three pass - Review for random error & take action if appropriate
 - One out of three pass - Unacceptable performance, Review for systematic error
 - All failed - Unacceptable performance. Review for systematic error

Dr Puneet Kumar Nigam

Dr Puneet Kumar Nigam
PT coordinator & Technical Manager, MHL EQAS
Unit No. 409-416,
Commercial Building - 1A,
Kohinoor Mall, Kirol Road, Kurla (W),
Mumbai - 400070






HEALTH HORIZON DIAGNOSTICS

**METROPOLIS HEALTHCARE LTD.
EXTERNAL QUALITY ASSURANCE SERVICE
(MHL EQAS PROGRAM)**

**CORRECTIVE AND PREVENTIVE ACTION
FOR
UNACCEPTABLE RESULTS OF
SERUM CHLORIDE TEST**

SR. NO	LIST OF DOCUMENTS
01	Annexure: 01: Instrument service Report
02	Annexure: 02: Internal Quality Control Data Date of 17/01/2023 & 30/01/2023
03	Annexure: 03: Internal Quality Control BIO-RAD Value Sheet Lot No. 26490, Level 01 :26491 & Level 02: 26492
04	Annexure: 04: Inter-Lab Comparison (ILC) Report
05	Annexure: 05: MOU with NABL Accredited Lab for Outsource Investigation

	FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS	
	ANNEXURE-01	HEALTH HORIZON DIAGNOSTICS

Type of Evaluation: External Quality Control / Proficiency Testing (PT) Sample

Other (Specify): _____

Evaluation Date: 25/01/2023

Investigation: Hematology Biochemistry Urine Serology Immunology

Other (Specify): _____

Unacceptable Analyte/ Parameter:


MHL EQAS Sample NO:01 = chloride
Sample NO:02 = chloride

Description/Error/ Reason/ Remark:

MHL EQAS Sample NO:01 - SDI Z-score = 3.55 Unacceptable
Sample NO.02 - SDI Z-score = 3.40 Unacceptable

Investigations (Root Cause Analysis) :

Phase	Commonest Reasons	Tick / Cross
Pre-Analytical Phase	1. Missed Test Requisition Form (TRF)	<input type="checkbox"/>
	2. Incorrect sample identification	<input type="checkbox"/>
	3. Incorrect sample tube	<input type="checkbox"/>
	4. Sample from IV running area	<input type="checkbox"/>
	5. Delay in sample transportation	<input type="checkbox"/>
	6. Insufficient samples	<input type="checkbox"/>
	7. Sample mix-ups	<input type="checkbox"/>
	8. Tube broken in centrifuge	<input type="checkbox"/>
	9. Wrong timing for Collection	<input type="checkbox"/>
	10. Invalid Specimen: Haemolysed Sample, Lipemic Sample and Icteric Sample	<input type="checkbox"/>
	11. Software errors	<input type="checkbox"/>
Analytical Phase	1. Instrument not calibrated properly	<input type="checkbox"/>
	2. Specimen mix-up	<input type="checkbox"/>
	3. Inadequate specimen	<input type="checkbox"/>
	4. Presence of interfering substances	<input type="checkbox"/>
	5. Wrong analytical method	<input type="checkbox"/>
	6. Lack of precision	<input type="checkbox"/>
Post-Analytical Phase	1. Wrong patient identification	<input type="checkbox"/>
	2. Report not legible	<input type="checkbox"/>
	3. Report delayed	<input type="checkbox"/>
	4. Transcriptional error	<input type="checkbox"/>
	5. Specificity of the test not understood	<input type="checkbox"/>
	6. Previous values are not available for comparison	<input type="checkbox"/>

	FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS	
	ANNEXURE-01	HEALTH HORIZON DIAGNOSTICS

Root Cause Analysis : We checked the Internal quality control of the date when EQAS was run, and found it within acceptable range. Also the specimen handling was cross checked as per our QSP "Handling proficiency Testing and External quality Assurance Sample (HHD-QSP/009/00)

Corrective Action: Corrective action taken on date 25/01/23. We checked Internal Quality Control record on date 17/01/2023, IAC result was within range. Also the preventive maintenance of the machine was done by service engineer.

Preventive Action: For the machine Easylyte Plus on date 30/01/2023 after maintenance IAC performed and it was within range. We have established MOU with a NABL LAB and have planned ILC of serum chloride every three months.

Conclusion Serum chloride had a PT outlier and accordingly CAPA was taken.

Attachment (Attach result form and assessment details):

Attached scan copy:

1) Instrument service Report	4) MOU with NABL Lab
2) Internal quality control data on date 17/01/2023 & 30/01/2023	5) Inter Lab comparison (ILC) Data.
3) IQC BIO-RAD Value sheet Lot NO- 26490, Level-01 26491 Level 02 - 26492	

Comment : Nil

Shamsher
30/01/2023

Recorded By : Sign / Date (Laboratory Manager /Authorized trained person)

Comment : Satisfactory

Alahoti
30/01/2023

Verified By : Sign / Date (Laboratory Director/Authorized trained person)

ANNEXURE : 01

TECHNICAL SERVICE REPORT

No. 1517043

DATE: 30/01/23

CUSTOMER DETAILS	INSTRUMENT DETAILS	SERVICE STATUS
NAME: Health	MODEL: EasyLife	<input type="checkbox"/> WARRANTY <input type="checkbox"/> R&R <input type="checkbox"/> AMC <input type="checkbox"/> CMC <input type="checkbox"/> CHARGED CALL
ADDRESS: Horizon Diagnosis Pune	SR. NO.: 56879	TYPE OF CALL <input type="checkbox"/> INSTALLATION <input type="checkbox"/> P.M. VISIT <input type="checkbox"/> I <input type="checkbox"/> II <input type="checkbox"/> III <input type="checkbox"/> IV <input type="checkbox"/> APPLICATION SUPPORT <input type="checkbox"/> BREAKDOWN
	CALL DETAILS	
TEL NO.:	COMPLAINT RECD.	DATE
NAME OF THE OPERATOR:	RESPONSE	TIME
	JOB COMPLETED	
PROBLEM REPORTED:	RESPONSE TIME	DOWN TIME:
	TRAVEL TIME	COUNTER READING:

OBSERVATIONS: cloude low
found same as above

ACTION TAKEN: Replaced probe
value pump tubing cleaned solution
Novalk

SITE CONDITION : LINE-NEUTRAL VOLT. : 220 ✓ NEUTRAL-EARTH VOLT. : 220 ✓ LINE-EARTH VOLT. : 220

BRAND OF REAGENT USED :					TO BE FILLED IN BY CUSTOMER		
<input type="checkbox"/> FOLLOWING PARTS HAVE BEEN REPLACED					<input checked="" type="checkbox"/> PREVENTIVE MAINTENANCE CARRIED OUT SATISFACTORILY.		
<input type="checkbox"/> FOLLOWING PARTS NEED TO BE REPLACED. PLEASE APPROVE					<input type="checkbox"/> FAULT RECTIFIED & INSTRUMENT IS WORKING SATISFACTORILY.		
NO.	DESCRIPTION	QTY.	COST	TOTAL	<input type="checkbox"/> WE HEREBY APPROVE RS _____ FOR PARTS		
					<input type="checkbox"/> COMMENTS (IF ANY):		
TOTAL Rs.					SEAL	DATE	CUSTOMER'S SIGNATURE NAME
						30/01/23	<i>Eshwar...</i>

INVOICE NO. :	DATE :	BRANCH	H. O.
FOLLOW-UP ACTION (Required if any):		RECEIVED ON :	
		CHECKED BY :	
ENGINEER'S/APPLICATION SPECIALIST'S SIGNATURE :		JOB CARD NO. :	
TIME: 11:30/12:30 NAME: Amrut Kulkarni			

NOTE: Parts replaced are chargeable except during warranty period. Consumables like printer head lamp, tubing, paper rolls etc. & breakable parts are not covered by warranty and hence are chargeable. Parts replaced due to negligence in operation will also be charged in every case.

AT TRANSASIA, CUSTOMER SATISFACTION IS OUR PRIME CONCERN. IN CASE YOU HAVE ANY SUGGESTIONS PLEASE CONTACT : GENERAL MANAGER (TECHNICAL SERVICE), MUMBAI, TEL. : 4030 9000

TRANSASIA BIO-MEDICALS LTD.
 Head Office : Transasia House, 8, Chandivall Studio Road, Andheri (E), Mumbai - 400 072. Tel. : (022) 4030 9000 Fax : (022) 2857 303
 Mumbai : Toll Free No. 1800 103 8226, Whatsapp No. : 8451048434, SMS No. : 9212433444
 Indore : Tel. : (0731) 403 3948 Chennai : Tel. : (044) 2822 7149 Kolkata : Tel. : (033) 2215 7838 Fax : 2215 803
 Lucknow : Tel. : (0522) 443 0900 Pune : Tel. : (020) 2618 2658 Dehi : Tel. : (011) 2578 5451/2573 2223
 Chandigarh : Tel. : (0172) 464 3637 Hyderabad : Tel. : (040) 4430 9000 Ahmedabad : Tel./Fax : (079) 02640 7030/4032 1903
 Jaipur : Tel. : 93092 63147 Guwahati : Tel. : 91369 50480 Bangalore : Tel./Fax : (080) 2556 8044
 Patna : Tel. : 77669 08553 Chittack : Tel. : (0871) 232 4555
 Kochi : Tel. : (0484) 402 6511 Hubli : Tel. : (0836) 485 0900

ANNEXURE : 02

Internal Quality Control for Chloride

Date:- 17/01/2023

JAN-17-23; 10:26

ANALYSIS

PATIENT'S NAME

BIO-RAD.

Control-Level-02

SAMPLE 003

Na 123.6 K 5.72 Cl 87.1 ✓

Na LO K HI Cl LO

BLOOD Na, K, Cl mmol/L

(CORRELATED VALUES)

JAN-17-23; 10:27

Done By:-

Santosh
17/01/2023

Checked By:-

Elmer
17/01/2023

Internal quality control for chloride date:- 30/01/2023

OPER FUNCTS

Na= 1.03X - 1.10
K = 1.02X - 0.24
Cl= 0.99X + 3.46
BLOOD CORRELATION ON
JAN-30-23; 12:23

Na/K/Cl
5EAB
MODE 00A

OPER FUNCTS

SOL'N PURGE
JAN-30-23; 12:25

CALIBRATION

CAL VALUES
Na 56.93 K 56.97 Cl 45.16
JAN-30-23; 12:29

ANALYSIS

PATIENT'S NAME

Pre-Run check Value.

SAMPLE 003
Na 134.0 K 6.28 Cl 96.8
Na LO K HI Cl LO
BLOOD Na, K, Cl mmol/L
(CORRELATED VALUES)
JAN-30-23; 12:40

ANALYSIS

PATIENT'S NAME

BIORAD GC
Level- 2

SAMPLE 004
Na 126.4 K 5.81 Cl 90.0 ✓
Na LO K HI Cl LO
BLOOD Na, K, Cl mmol/L
(CORRELATED VALUES)
JAN-30-23; 12:46

Done By:-

Santosh
30/01/2023

Checked By:-

Shankar
30/01/2023

ANNEXURE : 03

Lyphochek® Assayed Chemistry Control Levels 1 and 2

REF	C-310-5 Level 1 12 x 5 mL C-315-5 Level 2 12 x 5 mL 313X MiniPak 2 x 5 mL	CE 0459	IVD	EXP 2023-11-30	LOT 26490	Level 1 26491 Level 2 26492
------------	--	----------------	------------	-----------------------	------------------	--------------------------------



<https://www.myeinserts.com/26490>

INTENDED USE

Lyphochek Assayed Chemistry Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.

SUMMARY AND PRINCIPLE

The use of quality control materials is indicated as an objective assessment of the precision of methods and techniques in use and is an integral part of good laboratory practices. Multiple levels of control are available to allow monitoring of the test system's reliability.

For customers in Germany: Quality control materials are required for assessment of laboratory performance as described in the "Guideline for Quality Assurance of Medical Laboratory Examinations following the German Medical Association" (Rili-BÄK regulation).

REAGENT

This product is prepared from human serum with added chemicals, purified biochemical material (tissue extracts of human and animal origin), therapeutic drugs, stabilizers and preservatives. This product is provided in lyophilized form for increased stability.

STORAGE AND STABILITY

This product will be stable until the expiration date when stored unopened at 2 to 8°C.

Reconstituted and Refrigerated: After reconstituting and storing tightly capped at 2 to 8°C, this product will be stable as follows:

- All analytes: 7 days

Except:

- T3 (Free), Acid Phosphatase (Total) and Prostatic Acid Phosphatase (PAP): 3 days

Reconstituted and Frozen: When reconstituted and stored tightly capped at -10 to -20°C, this product will be stable as follows:

- All analytes: 30 days

Except:

- Tobramycin: 20 days

- T3 (Free): 10 days

Once thawed, do not refreeze this product. Discard the remaining material.

This product is shipped under ambient conditions.

PROCEDURE

This product should be treated the same as patient specimens and run in accordance with the instructions accompanying the instrument, kit, or reagent being used.

Using a volumetric pipet or equivalent, reconstitute each vial with 5.0 mL of distilled or deionized water. Replace the stopper and allow this product to stand for approximately 20 minutes swirling occasionally.

Before sampling, gently swirl the vial several times to ensure homogeneity. If performing trace metal analysis, do not mix by inversion. After each use, promptly replace the stopper and return to the appropriate storage condition.

Dispose of any discarded materials in accordance with the requirements of your local waste management authorities. In the event of damage to packaging, contact the local Bio-Rad Laboratories Sales Office or Bio-Rad Laboratories Technical Services.

LIMITATIONS

1. This product should not be used past the expiration date.
2. If there is evidence of microbial contamination or excessive turbidity in the reconstituted product, discard the vial.
3. This product is not intended for use as a standard.

WARNING



Biological source material. Treat as potentially infectious.

Each human donor unit used to manufacture this product was tested as required by FDA accepted methods. Tests results were non-reactive or negative for evidence of infection due to Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV). This product may also contain other human source materials for which there are no approved tests. In accordance with good laboratory practice, all human source material should be considered potentially infectious and handled with the same precautions used with patient specimens.

Safety Data Sheet (SDS) available for professional users on www.bio-rad.com.

SPECIFIC PERFORMANCE CHARACTERISTICS

This product is a freeze-dried product manufactured under rigid quality control standards. To obtain consistent assay values, the control requires proper storage and handling as described.

ASSIGNMENT OF VALUES

The mean values and corresponding $\pm 3SD$ ranges in the Assignment of Values Data Charts (available separately) were derived from replicate analyses and are specific for this lot of product. Data from Unity™ Interlaboratory Program are included in the determination of some ranges. The tests listed were performed by the manufacturer and/or independent laboratories using manufacturer supported reagents and a representative sampling of this lot of product. It is recommended that each laboratory establish its own acceptable ranges and use those provided only as guides. Laboratory established ranges may vary from those listed during the life of this control. [Customers in Germany have to follow the requirements as described in the Rili-BÄK regulation.] Variations over time and between laboratories may be caused by differences in laboratory technique, instrumentation and reagents, or by manufacturer test method modifications.

Unity™ Interlaboratory Program is a proprietary Bio-Rad software program holding more than 2 billion QC data points from thousands of laboratories.

INSTRUCTIONS FOR OBTAINING THE DATA CHARTS

The Data Charts are available through the Internet, at www.myeinserts.com/26490. Follow the directions at the website to receive email notifications of insert updates. Alternate methods for receiving data charts are available by contacting your local Bio-Rad Laboratories Office.

UNITED STATES, Bio-Rad Laboratories
9500 Jeronimo Road, Irvine, CA 92618

EC REP

FRANCE, Bio-Rad
3 boulevard Raymond Poincaré, 92430 Marnes-la-Coquette
Phone: (33) 1-4795-6000 / Fax: (33) 1-4741-9133

CH REP

SWITZERLAND, DiaMed GmbH
Pra Rond 23, 1785 Cressier FR



SWITZERLAND, Bio-Rad Laboratories AG
Pra Rond 23, 1785 Cressier FR



**Bio-Rad
Laboratories, Inc.**

**Clinical
Diagnostics Group**

9500 Jeronimo Road
Irvine, California 92618
(800) 854-6737
FAX (949) 598-1550
bio-rad.com/qualitycontrol


Technical Services:
(800) 854-6737

- Australia**, Bio-Rad Laboratories Pty. Ltd., u1A, 62 Fernhill Street, South Granville, New South Wales 2142 • Phone +61 (2) 9914 2800 • Fax +61 (2) 9914 2888
- Austria**, Bio-Rad Laboratories Ges.m.b.H., Hummelgasse 88/3-6, A-1130 Vienna • Phone +43 (0) 1 877 89 01 9 • Fax +43 (0) 1 876 56 29
- Belgium**, Bio-Rad Laboratories N.V., Wittinglaan 3, BE-9140 Ternse • Phone +32 (0) 3 710 53 00 • Fax +32 (0) 3 710 53 01
- Brazil**, Bio-Rad Laboratórios Brasil Ltda, Avenida Doutor Chucri Zaidan, 1.240 cj 1902 e 1904 Morumbi Corporate Santo Amaro, São Paulo, SP CEP 04711-130 • Phone +55 11 3065 7550
- Canada**, Bio-Rad Laboratories Ltd., 2403 Guénette Street, Montréal, Québec H4R 2E9 • Phone +1 514 334 4372 • Fax +1 514 334 0872
- China**, Bio-Rad Laboratories (Shanghai) Co., Ltd. Room 601, Allian Plaza, No. 168 Jingzhou Road, Yangpu District, Shanghai 200082 • Phone +86 21 6169 8500 • Fax +86 21 6169 8599
- Czech Republic**, Bio-Rad spol. s r.o., Ptkrtova 1737/1a, 14000 Prague 4 • Phone +420 241 431 660
- Denmark**, Bio-Rad Laboratories, Symbion Science Park, Fruebjergvej 3, DK-2100 Copenhagen East • Phone +45 44 52 10 00 • Fax +45 44 52 10 01
- Finland**, Bio-Rad Finland Oy, Kutomotie 16 FI-000380, Helsinki • Phone +358 9 804 22 00
- France**, Bio-Rad, 3 boulevard Raymond Poincaré, 92430 Marnes-la-Coquette • Phone +33 (0) 1 47 95 60 00 • Fax +33 (0) 1 47 41 91 33
- Germany**, Bio-Rad Laboratories GmbH, Kapellenstraße 12, D-85622 Feldkirchen, Munich • Phone +49 (0) 89 31884 393 • Fax +49 (0) 89 31884 136
- Greece**, Bio-Rad Laboratories M.E.P.E. 2-4 Mesogion Ave. (Athens Tower) 11527 Ampelokipi, Athens • Phone +30 210 7774396 • Fax +30 210 7774376
- Hong Kong**, Bio-Rad Pacific Ltd., Unit 1101, 11/F DCH Commercial Centre, 25 Westlands Road, Quarry Bay • Phone +85 2 2789 3300 • Fax +85 2 2789 1257
- Hungary**, Bio-Rad Hungary Ltd., Futó utca 47-53, 1082, Budapest • Phone +36 1 459 6190 • Fax +36 1 459 6101
- India**, Bio-Rad Laboratories India Pvt. Ltd., EMAAR Digital Greens, 9th Floor, Tower A- Sector 61 Gurugram-122 102, Haryana 122 015 • Phone +91 124 4029300 • Fax +91 124 2398115
- Israel**, Bio-Rad Laboratories Ltd., 14 Homa Street, New Industrial Area, Rishon Le Zion 75150 • Phone +972 3 963 6025 • Fax +972 3 951 4129
- Italy**, Bio-Rad Laboratories S.r.l., Via Cellini 18/A, 20090 Segrate, Milan • Phone +39 024 94 86 600 • Fax +39 02 21609399
- Japan**, Bio-Rad Laboratories K.K., Tennoz Central Tower 20F, 2-2-24 Higashi-Shinagawa, Shinagawa-ku, Tokyo 140-0002 • Phone +81 3 6361 7070 • Fax +81 3 5463 8481
- Korea**, Bio-Rad Korea Ltd., 10th Floor, Hyunjuk Building, 832-41, Yeoksam-dong, Gangnam-gu, Seoul 135-080 • Phone +82 080 007 7373 • Fax +82 (2) 3472 7003
- Mexico**, Bio-Rad, S.A., Avenida Eugenia 197, Piso 10-A, Colonia Narvarte, Delegación Benito Juárez C.P. 03020 Mexico, D.F. • Phone +52 (55) 5488 7670 • Fax +52 (55) 1107 7246
- The Netherlands**, Bio-Rad Laboratories B.V., Postbus 222, 3900 AE Veenendaal • Phone +31 (0) 318 540 666 • Fax +31 (0) 318 542 216
- New Zealand**, Bio-Rad New Zealand, 189 Bush Road Rosedale, Auckland • Phone +64 (9) 415 2280 • Fax +64 (9) 415 2284
- Norway**, Bio-Rad Laboratories, Nydalsveien 33, 0484 Oslo • Phone +47 23 38 41 30 • Fax +47 23 38 41 39
- Poland**, Bio-Rad Polska Sp. z o.o., Przyokopowa 33, Level 4, Building A, 01-208, Warsaw • Phone +48 22 331 99 99 • Fax +48 22 331 99 88
- Portugal**, Bio-Rad Laboratories, Lda., Edifício Prime, Ave. Quinta Grande, 53 - Fracção 3B Alfragide 26114-521, Amadora • Phone +351 21 47 27 700 • Fax +351 21 47 27 777
- Russia**, Bio-Rad Laboratorii, 5 Nizhny Susalny Lane, Property 5A, Moscow • Phone +7 (495) 721-14-04 • Fax +7 (495) 721-14-12
- Singapore**, Bio-Rad Laboratories (Singapore) Pte. Ltd., 3A International Business Park Road, #11-10/16, ICON @ IBP Tower B, Singapore 609935 • Phone +65 6415 3170 • Fax +65 6415 3189
- South Africa**, Bio-Rad Laboratories (Pty) Ltd., 34 Bolton Ave, Rosebank, Johannesburg • Phone +27 11 442 8508 • Fax +27 11 442 8525
- Spain**, Bio-Rad Laboratories, S.A., C/ Caléndula, 95, Edificio M. Miniparc II, El Soto de la Moraleja, 28109 Alcobendas • Phone +34 91 490 6560 • Fax +34 91 590 5211
- Sweden**, Bio-Rad Laboratories A.B., Solna Strandväg 3, SE-171 54 Solna, P.O. Box 1097, SE-172 22 Sundbyberg • Phone +46 844 98053 • Fax +46 8 55 51 27 80
- Switzerland**, Bio-Rad Laboratories AG, Pra Rond 23, CH-1785 Cressier • Phone +41 (0) 61 717 9555 • Fax +41 (0) 61 717 9550
- Taiwan**, Bio-Rad Laboratories Taiwan Ltd., 14th F B, No. 126, Sec. 4, Nan-King East Road, Taipei 10546 Taiwan, R.O.C. • Phone +886 (2) 2578-7189 • Fax +886 (2) 2578-6890
- Thailand**, Bio-Rad Laboratories Ltd., 1st & 2nd Floor, Lumpini I Bldg., 239/2 Rajdamri Road, Lumpini, Pathumwan, Bangkok 10330 • Phone (662) 651 8311 • Fax (662) 651 8312
- United Kingdom**, Bio-Rad Laboratories Ltd., The Junction Station Road, Watford, Hertfordshire, WD17 1ET • Phone +44 (0) 1923 471301 • Fax +44 (0) 1923 471340

INSTRUMENT (1)

	Units	Level 1 - 26491		Level 2 - 26492	
		Mean	Range	Mean	Range
BIOSYSTEMS B400/A25/A15 (5) (continued)					
Urea (Urease, UV) (4)	mg/dL	29.9	25.4 – 34.4	91.0	77.4 – 105
Uric Acid (Uricase, colorimetric)	mg/dL	4.91	4.17 – 5.65	8.58	7.29 – 9.87
ERBA XL SERIES (5)					
Albumin	g/dL	3.90	3.30 – 4.50	2.70	2.28 – 3.12
Albumin (India Market Only)	g/dL	3.96	3.36 – 4.56	2.69	2.30 – 3.08
Alkaline Phosphatase (IFCC Optimized) (2)	U/L	115	92.1 – 138	487	391 – 583
Alkaline Phosphatase (India Market Only) (2)	U/L	115	91.0 – 139	476	380 – 572
ALT/SGPT (2)	U/L	27.6	22.2 – 33.0	104	83.5 – 125
ALT/SGPT (Modified IFCC) (India Market Only) (2)	U/L	27.4	22.0 – 32.8	102	81.0 – 122
Amylase (2)	U/L	60.5	48.5 – 72.5	393	315 – 471
AST/SGOT (2)	U/L	38.2	30.7 – 45.7	204	162 – 246
AST/SGOT (Modified IFCC) (India Market Only) (2)	U/L	37.1	29.6 – 44.6	199	160 – 238
Bilirubin (Direct)	mg/dL	0.370	0.280 – 0.460	1.31	0.980 – 1.64
Bilirubin (Direct) (DCA)	mg/dL	0.390	0.300 – 0.480	1.65	1.23 – 2.07
Bilirubin (Total)	mg/dL	0.990	0.750 – 1.23	4.77	3.57 – 5.97
Bilirubin (Total) (DCA)	mg/dL	1.01	0.770 – 1.25	4.70	3.53 – 5.87
Calcium	mg/dL	9.94	8.44 – 11.4	13.4	11.3 – 15.5
Calcium (India Market Only)	mg/dL	9.21	7.83 – 10.6	12.3	10.5 – 14.1
Carbon Dioxide (CO2)	mEq/L	34.5	27.6 – 41.4	19.0	15.2 – 22.8
Chloride	mEq/L	107	96.0 – 118	93.0	83.7 – 102
Chloride (Mercuric Thiocyanate)	mEq/L	109	94.0 – 124	101	86.0 – 116
Cholesterol (HDL) (7)	mg/dL	67.2	53.7 – 80.7	23.9	19.1 – 28.7
Cholesterol (LDL)	mg/dL	149	119 – 179	67.6	54.1 – 81.1
Cholesterol (Total)	mg/dL	251	212 – 290	104	88.0 – 119
Cholinesterase (2)	U/L	7492	5995 – 8989	1131	906 – 1356
Creatine Kinase (CK) (2)	U/L	141	114 – 168	463	370 – 556
Creatinine (Alkaline picrate method)	mg/dL	2.59	2.08 – 3.10	5.74	4.60 – 6.88
Creatinine (Enzymatic)	mg/dL	1.80	1.44 – 2.16	5.21	4.16 – 6.26
Creatinine (Enzymatic) (India Market Only)	mg/dL	1.66	1.33 – 1.99	4.80	3.90 – 5.70
Gamma Glutamyltransferase (GGT) (2)	U/L	66.3	53.1 – 79.5	167	134 – 200
Glucose	mg/dL	91.7	77.9 – 106	304	259 – 349
Glucose (Hexokinase) (India Market Only)	mg/dL	85.4	72.5 – 98.3	285	243 – 327
Iron	µg/dL	236	188 – 284	62.1	49.8 – 74.4
Iron (UIBC)	µg/dL	63.3	50.7 – 75.9	126	102 – 150
Lactate Dehydrogenase (LDH) (2)	U/L	333	267 – 399	888	711 – 1065
Lipase (2)	U/L	43.1	34.4 – 51.8	57.7	46.3 – 69.1
Lithium	mEq/L	0.460	0.400 – 0.520	1.71	1.53 – 1.89
Magnesium	mg/dL	1.91	1.61 – 2.21	4.49	3.83 – 5.15
Phosphorus (India Market Only)	mg/dL	3.87	3.30 – 4.44	7.20	6.00 – 8.40
Phosphorus (New Formulation)	mg/dL	3.91	3.31 – 4.51	7.74	6.57 – 8.91
Potassium	mEq/L	3.61	3.25 – 3.97	5.49	4.95 – 6.03
Protein Serum (Total)	g/dL	6.94	5.89 – 7.99	4.75	4.03 – 5.47
Protein Serum (Total) (India Market Only)	g/dL	6.51	5.52 – 7.50	4.30	3.70 – 4.90
Sodium	mEq/L	140	126 – 154	123	110 – 135
Triglycerides	mg/dL	186	159 – 213	96.1	81.7 – 111
Triglycerides (India Market Only)	mg/dL	182	155 – 209	82.6	70.3 – 94.9
Urea (4)	mg/dL	33.8	28.7 – 38.9	103	88.0 – 118
Uric Acid	mg/dL	5.38	4.57 – 6.19	10.8	9.30 – 12.3

ANNEXURE : 04

 Health Horizon DIAGNOSTICS	ASSESSMENT OF INTER-LAB COMPARISON FOR LAB ANALYTES		Page 1 of 2
	ANNEXURE - 01	HEALTH HORIZON DIAGNOSTICS	

INTER-LAB COMPARISON :

DATE : 30/03/2023

Criteria: - One sample analyzed in the lab and same sample was send to NABL Accredited Lab for Inter-Lab Comparison.

Test Performed By:- DR. Santosh Hake

ANALYTE NAME	HEALTH HORIZON DIAGNOSTICS ANALYTE RESULT		AG DIAGNOSTICS NABL ACCREDITED LAB ANALYTE RESULT		Actual Result %CV	Evaluation Criteria %CV	Acceptable		Performed By
	Sample - 01	Sample - 02	Sample - 01	Sample - 02			Yes	NO	
Serum Chloride	92.8	---	92.0	---	0.61	5% or $\pm 3SD$	<input checked="" type="checkbox"/>	<input type="checkbox"/>	DR. Santosh Hake 30/03/2023


Health Horizon Diagnostics Chloride Sample 01 Result = 92.8

NABL Accredited AG Diagnostics Chloride Sample 01 Result = 92.0

Comparison Sample Mean = 92.4,

Comparison Sample SD = 0.56,

Comparison Sample CV = 0.61

 Health Horizon <small>DIAGNOSTICS</small>	ASSESSMENT OF LOT TO LOT/BATCH TO BATCH VERIFICATION FOR BIOCHEMISTRY	
	ANNEXURE - 01	HEALTH HORIZON DIAGNOSTICS

Note*: Evaluation Criteria referred from MHL EQAS Program PT Sample Participant Summary.
 For Inter-Lab Comparison Chloride result evaluation acceptable range = 5 % CV is acceptable or $\pm 3SD$

Remark: NA

Checked By: Shahid 30/03/2023

Technical Manager

Remark: Nil. Inter-lab comparison was evaluated within acceptable range.

Reviewed by: Shahid 30/03/2023
LabHead/ Quality Manager

Lab ID : 00466 /OPD
Patient Name : MR. MOHAMMAD ISRAFIL
Age / Sex : 75 Years / Male
Referred By : APPLE HOSPITAL
Lab Regn Date & Time : 30-Mar-2023 13:42
Coll. Date & Time : 30-Mar-2023 13:42
Report Date & Time : 30-Mar-2023 15:13
Sample Type : SERUM

Barcode



BIOCHEMISTRY.

Investigation	Result	Unit	Bio. Ref. Range
KIDNEY FUNCTION TEST			
Blood Urea (Method : Urease)	85.9	mg/dL	12.8-42.8
Creatinine (Method : Enzymatic)	1.17	mg/dL	0.6-1.3
Sr. Uric Acid Method : (Uricase/Peroxidase)	6.1	mg/dL	3.5-7.2
<i>Test Done on Fully Automated EM 200 Biochemistry Analyzer</i>			
ELECTROLYTES			
Sodium	121.0	mEq/lit	135-145
Potassium	5.47	mEq/lit	3.5-5.1
Chloride	92.8	mmol/L	98-107

Test done on Easy Lite -Fully Automated Electrolyte Analyser

END OF REPORT

Dr Ankeeta Lahoti
MD Pathology



MOHAMMAD ISRAFIL

Ref.:Dr.--

Sample Collected At:
Synergen Diagnostics
Unit 105, Sai Chambers, Wakadewadi,
Old Mumbai-Pune Highway,
Pune - 411003 Zone SHIVA

SID: 12222693

Collection Date:
30-03-2023 08:24 PM
Registration Date:
30-03-2023 08:24 pm
Report Date:
30-03-2023 08:59 PM

REPORT

Age:75.00 Years Sex:MALE

Test Description	Observed Value	Biological Reference Interval
Clinical Chemistry :		
Bilirubin-Total, serum by Diazo method	2.00	0.10 - 1.20 mg/dL Neonates : Upto 15.0 mg/dL
Bilirubin-Conjugated, serum by Diazo method	1.30	Upto 0.5 mg/dL
Bilirubin-Unconjugated, serum by calculation	0.70	0.1 to 1.0 mg/dL
Kindly correlate clinically and follow up.		
Chloride, serum by IMT Indirect	92.00	98 to 107 mmol/Lt
End of Report		



MC-3143

Shantanu Roy

Dr. Shantanu Roy
D.C.P., D.N.B. (Path)
Reg.No.-2013/02/0274
A.G Diagnostics Pvt. Ltd.

ANNEXURE : 05

AGREEMENT FOR PROVISION OF DIAGNOSTIC LABORATORY SERVICES

This agreement for **Provision of Diagnostic Laboratory Services** is executed on 01-03-2023.

BY AND BETWEEN

A.G Diagnostics Private Limited, a company incorporated under the provisions of companies act 2013 & having its office at Nayantara, Bhandarkar Road Pune 411004 (hereinafter referred to as "**AGD**" which expression shall, unless repugnant to the context thereof, mean and include its legal representatives, partners, administrators and permitted assigns), represented through its authorised signatory Mr. Amol Deshmukh of the one part.

AND

Health Horizon Diagnostics, whose details are specified under Annexure A (hereinafter referred to as the "**Client**" which expression shall, unless repugnant to the context thereof, mean and include its legal representatives, partners, administrators and permitted assigns) represented by Dr. Harshal Patil of the other part. AGD & the Client hereinafter also be collectively referred to as "**Parties**" & individually as the "**Party**".

WHEREAS

- AGD is engaged in providing reliable, fast and affordable Pathology laboratory and wellness services to patients, clinicians & other laboratories in and around Pune. AGD has best of equipment, technology & manpower of international standards with a sound infrastructure and properly laid down systems. AGD is accredited by NABL through Certificate No. MC-3143.
- The Client after the mutual discussions between both the Parties has agreed to avail services of AGD. In furtherance of the same, the Parties are desirous of entering into this Contract to record the terms and conditions subject to which AGD shall provide its Services, and the Client shall pay the fees.

Therefore, it is agreed to record the understanding between the parties on the terms & conditions as set forth below:

1. SERVICES:

- The Client hereby engages AGD to provide services listed in AGD's latest DOS and Annexure B.
- AGD will provide the services as per its Directory of Services (DOS). Changes if any shall be communicated to the Client 15 days in advance in writing. Client will make the necessary changes to its records & shall consider the changes as final.
- Client acknowledges that under unavoidable / unforeseen circumstances AGD may discontinue any service or change the method of testing without prior intimation to the Client. However, to minimize the impact on the patient / healthcare, the same will be intimated to the Client at earliest.
- If the samples are collected at the Client's premises, AGD shall offer Logistics support as described through Clause 2.

2. LOGISTICS:

- AGD shall arrange for the pickup of samples from the Client's premises on all the weekdays during working hours of AGD.
- AGD shall not provide logistic services on Sundays & public holidays.

Client Details

2.1. V3 B2B Agreement - Labs and Hospitals

Expertise Based On A Legacy Of Over Four Decades
A.G Diagnostics Pvt. Ltd., Registered Office: Nayantara, Bhandarkar Road, Pune 411004 INDIA
Tel: +91 20 6763 6763 | E-mail: info@agdiagnostics.com | www.agdiagnostics.com

CIN - U74999PN2017PTC172845

- 2.3 The representatives of both the parties will mutually decide on the periodicity of the sample pick up based on the workload.
- 2.4 AGD shall ensure that the samples are transported to the laboratory from the Client's premises in optimum storage conditions. It is responsibility of the Client to ensure packing in such a manner to ensure sample integrity during transit.
- 2.5 In event of sample loss due to unavoidable circumstances, AGD shall not be held responsible.
- 2.6 The responsibility for appropriate sample collection as per test requirements and labelling after correct patient identification and providing relevant clinical history in the Test Requisition Form remains with the client.

3. REPORTS:

- 3.1 AGD shall deliver the reports to the Client as per the Turnaround time committed in the DOS, however in unforeseen circumstances reports may be delayed. AGD agrees to ensure that the delay is minimal & the Client shall not raise any claim for refund or initiate any action against AGD.
- 3.2 Mode of delivery: It is agreed between the parties that preferred mode of delivery is Auto email services by AGD wherein the Client shall provide a correct email id on which reports shall be emailed by AGD. The responsibility towards appropriate access to this email id on the Client's end, remains with the Client. The email id for providing auto email provided by Client to AGD is as mentioned in Annexure A.
- 3.3 The hard copy shall be delivered by the Logistics person if the Client desires so.
- 3.4 It is further agreed between the parties that Auto Email Service shall not be available for tests inclusive of but not limited to where reports have graphics, attachment of certain kinds, two signatures etc. **Annexure C** includes the list of few such tests.

4. COMPENSATION FOR SERVICES:

- 4.1 The Invoice shall be generated Monthly based on test charges agreed upon through Annexure B and will be sent to the Client at its office mentioned in this agreement unless otherwise specified & agreed upon.
- 4.2 Clients shall check the Invoice & intimate any discrepancy to AGD within 5 working days. AGD will verify the same & shall amend the invoice accordingly, if necessary & resubmit to the Client. However, if the discrepancy is not reported, Client agrees to pay the entire invoice amount.
- 4.3 Client agrees to pay the invoice amount in 8 working days. Under any circumstances Client shall not withhold any payment. If there is any discrepancy, Client shall release remaining amount immediately & shall release the discrepant amount upon successful resolution of the issue reported, in any case not later than 30 days.

4.4 PAYMENT MODE:

4.4.1 **Cheque/Demand Draft (DD):** The Payment in favour of "A.G Diagnostics Pvt. Ltd".

4.4.2 **NEFT:** Details as below:

A/C Name : **A.G Diagnostics Pvt. Ltd.**

Bank Name : ICICI Bank Ltd

Branch : Bhandarkar Road-Pune

A/C No. : 624005020746

RTGS/NEFT IFSC code: ICIC0006240

MICR : 411229006

4.4.3 **Cash:** Clients shall prefer any of the above modes of payment & avoid cash payment. However, if such need arises the Client shall intimate AGD in writing. AGD shall not be responsible for any cash payments released without such intimation.

4.5 If the Client fails to pay within 15 days of receipt of invoice, AGD reserves the right to hold the services till the outstanding amount is cleared. In case of non-payment within agreed upon duration, AGD will charge interest @ 1.25% per month from the due date.

4.6 AGD PAN number is **AAQCA0978E**

Client Initials



5. DURATION/TERM:

5.1 This agreement shall commence from 01-03-2023 & will be in force up to 28-02-2026 for a period of 36 months.

6. RENEWAL:

6.1 The agreement may be renewed for a further period on mutual terms & conditions as agreed between the parties.

7. TERMINATION:

7.1 Either party can terminate this agreement by giving clear 30 days' notice in writing. Either party shall also be entitled to terminate this Agreement with immediate effect if any breach of terms and conditions contained in this agreement. Before terminating this agreement both parties agree to settle all dues towards each other.

8. CONFIDENTIALITY:

8.1 Either party shall not disclose and /or divulge to any person/s and /or companies any information related to the terms & conditions of this agreement. AGD agrees not to disclose to any third party any information with regards to the tests conducted by AGD.

9. DISPUTES & ARBITRATION:

- 9.1 If any dispute or difference of any kind whatsoever shall arise between the Parties in connection with or arising out of this agreement whether before or after the termination or breach of this agreement the Parties shall promptly & in good faith negotiate to find an amicable resolution & settlement.
- 9.2 In the event no amicable resolution or settlement is reached within a period of 30 days such a dispute or difference shall be referred to a mutually acceptable single arbitrator under the provisions of the Indian Arbitration & conciliation Act 1996. The arbitration proceedings shall be held in Pune.
- 9.3 Notwithstanding anything contained herein, the parties shall have the right to institute legal proceedings to prevent any such continuing breach of provisions of this Agreement to seek specific relief & the courts in Pune shall have exclusive jurisdiction on any matter arising out of this Agreement.

10. MISCELLANEOUS

10.1 **Intellectual Property Rights.** All intellectual property rights belonging to a Party prior or after the execution of this agreement shall remain vested in that Party. None of the intellectual property rights in either Party's trademarks and/or brands shall be used by the other Party for any purpose, without such other Party's prior written consent.

10.2 **Entire Agreement.** This agreement supersedes any earlier contracts, communications that may have been entered into between the Parties on the said subject matter. All the Annexures which are mentioned in this agreement, shall be treated as integral part of this agreement. It is clarified that AGD is entitled to amend the AGD DoS from time to time at its sole discretion. In the event AGD amends the DoS such updated AGD DoS shall be deemed to be incorporated into this Contract by reference and such amended AGD DoS shall be made available to the Client.

Client Initials





2.1. V3 B2B Agreement - Labs and Hospitals

AGD Initials



10.3 **Force Majeure.** If the compliance of its obligations under this Contract by either Party is delayed, prevented, restricted or interfered with by reason of Force Majeure then the Party so affected, upon giving prompt written notice to the other Party, shall not be liable for non-performance of such obligations.

IN WITNESS OF the Parties hereto have executed this Agreement on the date mentioned above

<p>For and on behalf of the Client:</p>   <hr/> <p>Name: Dr. Harshal Patil Title: Director</p>	<p>For and on behalf of AGD:</p>   <hr/> <p>Name: Mr. Amol Deshmukh Title: General Manager</p>
--	---

Client Initials




AGD Initials

2.1.1. V1
ANNEXURE A
 Client Details

Details of the Client:

Sl. #	Particulars Required	Details
1	Name of the Client	Health Horizon Diagnostics
2	Client Constitution	(Proprietorship/Partnership/ Private Ltd Co/Public Ltd Co)
3	Trade Licence No/CIN	Please provide Trade Licence No or CIN
4	Permanent Account No.	
5	Name(s) of Proprietor / Partners / Directors	1. Dr. Harshal Patil 2. Dr. Ankeeta Lahoti 3. 4. 5.
6	Email Id of Proprietor / Partners / Directors	1. hhdiagnostics@gmail.com 2. 3. 4. 5.
7	Nature of Business (Laboratory/Hospital/Others)	Laboratory
8	Office Address	Flat No. 401 & 402, CTS No.364,365/13,FP No.713, 714/13, Varun Capital, Shivaji Nagar,Pune-411005
9	Contact Person Name	Mr. Dhananjay Abhang
10	Contact Person Phone No.	8070000444
11	Contact Person e-mail ID for auto email services	synergendiagnosics@gmail.com
12	Authorised Signatory Name	Dr. Harshal Patil
13	Authorised Signatory Designation	Director
14	Authorised Signatory email address	hhdiagnostics@gmail.com
15	Bank details from where payments will be made to AGD	Bank Name: Account Name: Account Type: Savings/Current/OD/CC Bank Address: IFSC Code:

Client Initials



2.1.2. V1

ANNEXURE B**Commercials**

Subject to Clause 1, the term 'Services' shall mean any of the services detailed in column (B) hereto, which have been agreed to be provided by AGD in relation to the Samples. Also, subject to Clause 4.1, the term 'test charges' in relation to a Service shall mean the cost prescribed against such Service in column (C) below:

S. No.	Services (B)	Test Charges (C)
1)	All types of medical diagnostic laboratory services currently being provided by AGD. A list of all the tests currently being provided by AGD is provided in latest AGD DoS.	List Price as per AGD Directory of Services & discount structure as given below

Standard Discount Structure:

Sr. No	Category of Tests	Discount % on List Price in DoS
1	A3	30 %
2	A4	20 %
3	A5	10 %
4	A6	0 %


Special Discount:

Sr. No	Test	Test Charges (₹)	Discounted Charges (₹)
1	FSH	500	150
2	LH	500	150
3	Beta HCG	840	200
4	E2- Estradiol	700	200
5			
6			
7			
8			
9			
10			
11			
12			
13			
14			
15			
16			
17			
18			
19			
20			

Client Initials

2.1. V8 B2B Agreement - Labs and Hospitals

AGD Initials





2.1.3 V2.

ANNEXURE C

List of Tests excluded from Auto Email services.

Sr. No	Name of Test
1	Histopathology Reports
2	Double Marker Test- First Trimester
3	Triple Marker Test- Second Trimester
4	Quadruple Test
5	Hemoglobin Electrophoresis
6	Protein Electrophoresis
7	Immunofixation Electrophoresis






HEALTH HORIZON DIAGNOSTICS

**METROPOLIS HEALTHCARE LTD.
EXTERNAL QUALITY ASSURANCE SERVICE
(MHL EQAS PROGRAM)**

**CORRECTIVE AND PREVENTIVE ACTION
FOR
UNACCEPTABLE RESULTS OF
BILIRUBIN DIRECT TEST**

	FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS	
	ANNEXURE-01	HEALTH HORIZON DIAGNOSTICS

Type of Evaluation: External Quality Control / Proficiency Testing (PT) Sample

Other (Specify): _____

Evaluation Date: 25/01/2023

Investigation: Hematology Biochemistry Urine Serology Immunology

Other (Specify): _____

Unacceptable Analyte/ Parameter:


MHL EQAS Sample NO:02 = Bilirubin Direct.

Description/Error/ Reason/ Remark:

MHL EQAS: Bilirubin Direct.
Sample NO:02 = SDI Z-score = -2.32
Warning alert flag.

Investigations (Root Cause Analysis) :

Phase	Commonest Reasons	Tick / Cross
Pre-Analytical Phase	1. Missed Test Requisition Form (TRF)	<input type="checkbox"/>
	2. Incorrect sample identification	<input type="checkbox"/>
	3. Incorrect sample tube	<input type="checkbox"/>
	4. Sample from IV running area	<input type="checkbox"/>
	5. Delay in sample transportation	<input type="checkbox"/>
	6. Insufficient samples	<input type="checkbox"/>
	7. Sample mix-ups	<input type="checkbox"/>
	8. Tube broken in centrifuge	<input type="checkbox"/>
	9. Wrong timing for Collection	<input type="checkbox"/>
	10. Invalid Specimen: Haemolysed Sample, Lipemic Sample and Icteric Sample	<input type="checkbox"/>
	11. Software errors	<input type="checkbox"/>
Analytical Phase	1. Instrument not calibrated properly	<input type="checkbox"/>
	2. Specimen mix-up	<input type="checkbox"/>
	3. Inadequate specimen	<input type="checkbox"/>
	4. Presence of interfering substances	<input type="checkbox"/>
	5. Wrong analytical method	<input type="checkbox"/>
	6. Lack of precision	<input type="checkbox"/>
Post-Analytical Phase	1. Wrong patient identification	<input type="checkbox"/>
	2. Report not legible	<input type="checkbox"/>
	3. Report delayed	<input type="checkbox"/>
	4. Transcriptional error	<input type="checkbox"/>
	5. Specificity of the test not understood	<input type="checkbox"/>
	6. Previous values are not available for comparison	<input type="checkbox"/>

	FORMAT OF EXTERNAL QUALITY CONTROL/ PROFICIENCY TESTING (PT) SAMPLES: CORRECTIVE AND PREVENTIVE ACTION FOR UNACCEPTABLE RESULTS	
	ANNEXURE-01	HEALTH HORIZON DIAGNOSTICS

<p>Root Cause Analysis : MHL-EGAS Biochemistry Sample NO:02 Bilirubin Direct test run on ERBA EM-200 Analyser. Inl We checked the Internal quality control of the date when EGAS was run and found it within a acceptable range. Also PT(EGAS specimen handling was cross checked as per our QSP (Handling proficiency testing and External quality Assurance sample CHHD-QSP/009/00)</p>	
<p>Corrective Action: Corrective action taken on date 25/01/23 We checked Internal quality control record on date 17/01/2023. IQC result was within range. Also the preventive maintenance of the instrument was done by the service engineer.</p>	
<p>Preventive Action: For analyser. ERBA EM-200 on date 30/01/23 After maintenance IQC performed and it was within range.</p>	
<p>Conclusion serum Bilirubin Direct had a PT outlier, It was a warning signal and accordingly corrective and preventive action was taken.</p>	
<p>Attachment (Attach result form and assessment details): Attached scan copy:-</p>	
1) Instrument Service Report	—
2) Internal QC data on date 17/01/2023 & 30/01/2023 for Bilirubin Direct Test	
3) IQC BIORAD value sheet Lot NO. 26490 Level-02- 26492	
<p>Comment : Nil</p> <p style="text-align: right;"><i>Shahryar</i> 30/01/2023</p>	
<p>Recorded By : Sign / Date (Laboratory Manager /Authorized trained person)</p>	
<p>Comment : Satisfactory</p> <p style="text-align: right;"><i>Alahab</i> 30/01/2023</p>	
<p>Verified By : Sign / Date (Laboratory Director/Authorized trained person)</p>	

SR. NO	LIST OF DOCUMENTS
01	Annexure: 01: Instrument service Report
02	Annexure: 02: Internal Quality Control Data Date of 17/01/2023 & 30/01/2023
03	Annexure: 03: Internal Quality Control BIO-RAD Value Sheet Lot No. 26490, Level 01 :26491 & Level 02: 26492

ANNEXURE : 01

TECHNICAL SERVICE REPORT

No. 1517640

DATE: 30/01/23

CUSTOMER DETAILS		INSTRUMENT DETAILS		SERVICE STATUS	
NAME: Heath		MODEL: Emco		<input type="checkbox"/> WARRANTY	<input type="checkbox"/> IRR
ADDRESS: Horizon Diagonal Lane		SR. NO.: B1001319		<input checked="" type="checkbox"/> AMC	<input type="checkbox"/> CMC
TEL NO.:		CALL DETAILS		TYPE OF CALL	
NAME OF THE OPERATOR:		COMPLAINT REC'D	DATE	TIME	<input type="checkbox"/> INSTALLATION
PROBLEM REPORTED:		RESPONSE			<input checked="" type="checkbox"/> T.P.M. VISIT (I/II/III/IV)
		JOB COMPLETED			<input type="checkbox"/> APPLICATION SUPPORT
		RESPONSE TIME			<input type="checkbox"/> BREAKDOWN
		TRAVEL TIME		1 1/2	DOWN TIME:
					COUNTER READING:

OBSERVATIONS: Nil

ACTION TAKEN: Preventive maintenance

Done pm as per protocol

clean both chamber. Replaced lamp

Replaced laundry tubings clean lamp cooling path

All filter replaced

SITE CONDITION: LINE-NEUTRAL VOLT.: 230V NEUTRAL-EARTH VOLT.: 0V LINE-EARTH VOLT.: 230V

BRAND OF REAGENT USED:

NO.	DESCRIPTION	QTY.	COST	TOTAL
TOTAL Rs.				

TO BE FILLED IN BY CUSTOMER

PREVENTIVE MAINTNANCE CARRIED OUT SATISFACTORILY.

FAULT RECTIFIED & INSTRUMENT IS WORKING SATISFACTORILY.

WE HEREBY APPROVE RS. _____ FOR PARTS

COMMENTS (IF ANY):

SEAL: _____ DATE: 30/01/23 CUSTOMER'S SIGNATURE: [Signature] NAME:

INVOICE NO.: _____ DATE: _____

FOLLOW-UP ACTION (Required if any): _____

RECEIVED ON: _____ BRANCH: _____ H.O: _____

CHECKED BY: _____

ENGINEER'S/APPLICATION SPECIALIST'S SIGNATURE: [Signature] NAME: Arvind Kulkarni

TIME: 12:50 PM

JOB CARD NO.:

NOTE: Parts replaced are chargeable except during warranty period. Consumables like printer head, lamp, tubing, paper rolls etc. & breakable parts are not covered by warranty and hence are chargeable. Parts replaced due to negligence in operation will also be charged in every case.

AT TRANSASIA, CUSTOMER SATISFACTION IS OUR PRIME CONCERN. IN CASE YOU HAVE ANY SUGGESTIONS PLEASE CONTACT: GENERAL MANAGER (TECHNICAL SERVICE), MUMBAI. TEL: 4030 9000

ANNEXURE : 02

Internal Quality Control BIO-RAD Level - 2

Result Reprint

Report Type : Controls

Sr #	Lot #	Consumable	Test	Result Unit	Flag	Curve #	Result Date	Mean	SD	Interval (3SD)
1	26492	BIORAD LEVEL 2	SGPTD	107.9 U/L		84511	17-Jan-2023 10:43:24	102.000	6.800	81.6 - 122.4
2	26492	BIORAD LEVEL 2	SGOTD	196.9 U/L		84512	17-Jan-2023 10:43:42	199.000	12.990	160.03 - 237.97
3	26492	BIORAD LEVEL 2	ALPU	449 U/L	-1SD	84513	17-Jan-2023 10:44:00	487.000	32.000	391 - 583
4	26492	BIORAD LEVEL 2	BID	1.54 mg/dl	+2SD	84514	17-Jan-2023 10:44:18	1.310	0.110	0.98 - 1.64
5	26492	BIORAD LEVEL 2	BIT	5.19 mg/dl	+1SD,HV!	84515	17-Jan-2023 10:44:36	4.770	0.400	3.57 - 5.97
6	26492	BIORAD LEVEL 2	UREA	95.9 mg/dl	-1SD	84516	17-Jan-2023 10:44:54	103.000	5.000	88 - 118
7	26492	BIORAD LEVEL 2	CRENZ	5.44 mg/dl		84517	17-Jan-2023 10:45:12	5.210	0.350	4.16 - 6.26
8	26492	BIORAD LEVEL 2	GLU	302.0 mg/dl		84518	17-Jan-2023 10:45:30	304.000	15.000	259 - 349
9	26492	BIORAD LEVEL 2	TRIG	92.5 mg/dl	HV!	84519	17-Jan-2023 10:45:48	96.100	4.960	81.22 - 110.98
10	26492	BIORAD LEVEL 2	CHOL	97 mg/dl	-1SD	84520	17-Jan-2023 10:46:06	104.000	5.000	89 - 119
11	26492	BIORAD LEVEL 2	HDLC	24.3 mg/dl		84521	17-Jan-2023 10:46:24	23.900	1.600	19.1 - 28.7
12	26492	BIORAD LEVEL 2	UA	11.1 mg/dl		84522	17-Jan-2023 10:46:42	10.800	0.500	9.3 - 12.3
13	26492	BIORAD LEVEL 2	ALB	2.72 g/dl		84523	17-Jan-2023 10:47:01	2.690	0.130	2.3 - 3.08
14	26492	BIORAD LEVEL 2	PRO	4.67 g/dl		84524	17-Jan-2023 10:47:19	4.750	0.240	4.03 - 5.47

Checked By:-
Dhanraj
17/01/23

Done By:- Jantavi
17/01/23

Print Date 17-Jan-2023

Internal Quality Control BIORAD Level-2.

Result Reprint

Report Type : Controls

Sr #	Lot #	Consumable	Test	Result Unit	Flag	Curve #	Result Date	Mean	SD	Interval (3SD)
1	26492	BIORAD LEVEL 2	SGPTD	114.6 U/L	+1SD	98709	30-Mar-2023 10:57:35	102.000	6.800	81.6 - 122.4
2	26492	BIORAD LEVEL 2	SGOTD	216.1 U/L	+1SD	98710	30-Mar-2023 10:57:53	199.000	12.990	160.03 - 237.97
3	26492	BIORAD LEVEL 2	ALPU	479 U/L		98711	30-Mar-2023 10:58:11	487.000	32.000	391 - 583
4	26492	BIORAD LEVEL 2	BID	1.54 mg/dl	+2SD	98712	30-Mar-2023 10:58:29	1.310	0.110	0.98 - 1.64
5	26492	BIORAD LEVEL 2	BIT	4.61 mg/dl		98713	30-Mar-2023 10:58:47	4.770	0.400	3.57 - 5.97
6	26492	BIORAD LEVEL 2	UREA	105.4 mg/dl		98714	30-Mar-2023 10:59:05	103.000	5.000	88 - 118
7	26492	BIORAD LEVEL 2	CRENZ	5.31 mg/dl		98715	30-Mar-2023 10:59:23	5.210	0.350	4.16 - 6.26
8	26492	BIORAD LEVEL 2	GLU	285.5 mg/dl	-1SD	98716	30-Mar-2023 10:59:41	304.000	15.000	259 - 349
9	26492	BIORAD LEVEL 2	TRIG	83.5 mg/dl	-1SD	98717	30-Mar-2023 10:59:59	90.520	4.960	75.64 - 105.4
10	26492	BIORAD LEVEL 2	CHOL	107 mg/dl		98718	30-Mar-2023 11:00:17	104.000	5.000	89 - 119
11	26492	BIORAD LEVEL 2	HDLC	23.4 mg/dl		98719	30-Mar-2023 11:00:35	23.900	1.600	19.1 - 28.7
12	26492	BIORAD LEVEL 2	UA	10.5 mg/dl		98720	30-Mar-2023 11:00:53	10.800	0.500	9.3 - 12.3
13	26492	BIORAD LEVEL 2	ALB	2.58 g/dl		98721	30-Mar-2023 11:01:11	2.690	0.130	2.3 - 3.08
14	26492	BIORAD LEVEL 2	PRO	4.46 g/dl	-1SD	98722	30-Mar-2023 11:01:29	4.750	0.240	4.03 - 5.47

Done by:-
[Signature]
 30/03/23


Checked By:
[Signature]
 30/03/23

ANNEXURE : 03

Lyphochek® Assayed Chemistry Control Levels 1 and 2



C-310-5 Level 1 12 x 5 mL
C-315-5 Level 2 12 x 5 mL
313X MiniPak 2 x 5 mL



Level 1 26491
Level 2 26492



<https://www.myinserts.com/26490>

INTENDED USE

Lyphochek Assayed Chemistry Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in this package insert.

SUMMARY AND PRINCIPLE

The use of quality control materials is indicated as an objective assessment of the precision of methods and techniques in use and is an integral part of good laboratory practices. Multiple levels of control are available to allow monitoring of the test system's reliability.

For customers in Germany: Quality control materials are required for assessment of laboratory performance as described in the "Guideline for Quality Assurance of Medical Laboratory Examinations following the German Medical Association" (Rili-BÄK regulation).

REAGENT

This product is prepared from human serum with added chemicals, purified biochemical material (tissue extracts of human and animal origin), therapeutic drugs, stabilizers and preservatives. This product is provided in lyophilized form for increased stability.

STORAGE AND STABILITY

This product will be stable until the expiration date when stored unopened at 2 to 8°C.

Reconstituted and Refrigerated: After reconstituting and storing tightly capped at 2 to 8°C, this product will be stable as follows:

- All analytes: 7 days

Except:

- T3 (Free), Acid Phosphatase (Total) and Prostatic Acid Phosphatase (PAP): 3 days

Reconstituted and Frozen: When reconstituted and stored tightly capped at -10 to -20°C, this product will be stable as follows:

- All analytes: 30 days

Except:

- Tobramycin: 20 days

- T3 (Free): 10 days

Once thawed, do not refreeze this product. Discard the remaining material.

This product is shipped under ambient conditions.

PROCEDURE

This product should be treated the same as patient specimens and run in accordance with the instructions accompanying the instrument, kit, or reagent being used.

Using a volumetric pipet or equivalent, reconstitute each vial with 5.0 mL of distilled or deionized water. Replace the stopper and allow this product to stand for approximately 20 minutes swirling occasionally.

Before sampling, gently swirl the vial several times to ensure homogeneity. If performing trace metal analysis, do not mix by inversion. After each use, promptly replace the stopper and return to the appropriate storage condition.

Dispose of any discarded materials in accordance with the requirements of your local waste management authorities. In the event of damage to packaging, contact the local Bio-Rad Laboratories Sales Office or Bio-Rad Laboratories Technical Services.

LIMITATIONS

1. This product should not be used past the expiration date.
2. If there is evidence of microbial contamination or excessive turbidity in the reconstituted product, discard the vial.
3. This product is not intended for use as a standard.

WARNING



Biological source material. Treat as potentially infectious.

Each human donor unit used to manufacture this product was tested as required by FDA accepted methods. Tests results were non-reactive or negative for evidence of infection due to Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV). This product may also contain other human source materials for which there are no approved tests. In accordance with good laboratory practice, all human source material should be considered potentially infectious and handled with the same precautions used with patient specimens.

Safety Data Sheet (SDS) available for professional users on www.bio-rad.com.

SPECIFIC PERFORMANCE CHARACTERISTICS

This product is a freeze-dried product manufactured under rigid quality control standards. To obtain consistent assay values, the control requires proper storage and handling as described.

ASSIGNMENT OF VALUES

The mean values and corresponding $\pm 3SD$ ranges in the Assignment of Values Data Charts (available separately) were derived from replicate analyses and are specific for this lot of product. Data from Unity™ Interlaboratory Program are included in the determination of some ranges. The tests listed were performed by the manufacturer and/or independent laboratories using manufacturer supported reagents and a representative sampling of this lot of product. It is recommended that each laboratory establish its own acceptable ranges and use those provided only as guides. Laboratory established ranges may vary from those listed during the life of this control. [Customers in Germany have to follow the requirements as described in the Rili-BÄK regulation.] Variations over time and between laboratories may be caused by differences in laboratory technique, instrumentation and reagents, or by manufacturer test method modifications.

Unity™ Interlaboratory Program is a proprietary Bio-Rad software program holding more than 2 billion QC data points from thousands of laboratories.

INSTRUCTIONS FOR OBTAINING THE DATA CHARTS

The Data Charts are available through the Internet, at www.myinserts.com/26490. Follow the directions at the website to receive email notifications of insert updates. Alternate methods for receiving data charts are available by contacting your local Bio-Rad Laboratories Office.



UNITED STATES, Bio-Rad Laboratories
9500 Jeronimo Road, Irvine, CA 92618



FRANCE, Bio-Rad
3 boulevard Raymond Poincaré, 92430 Marnes-la-Coquette
Phone:(33) 1-4795-6000 / Fax:(33) 1-4741-9133



SWITZERLAND, DialMed GmbH
Pra Rond 23, 1785 Cressier FR



SWITZERLAND, Bio-Rad Laboratories AG
Pra Rond 23, 1785 Cressier FR

**Clinical
Diagnostics Group**

9500 Jeronimo Road
Irvine, California 92618
(800) 854-6737
FAX (949) 598-1550
bio-rad.com/qualitycontrol

Technical Service:
(800) 854-6737

- Australia**, Bio-Rad Laboratories Pty. Ltd., u1A, 62 Fernhill Street, South Granville, New South Wales 2142 • Phone +61 (2) 9914 2300 • Fax +61 (2) 9914 2888
- Austria**, Bio-Rad Laboratories Ges.m.b.H., Hummelgasse 88/3-6, A-1130 Vienna • Phone +43 (0) 1 877 89 01 9 • Fax +43 (0) 1 876 56 29
- Belgium**, Bio-Rad Laboratories N.V., Winninglaan 3, BE-9140 Temse • Phone +32 (0) 3 710 53 00 • Fax +32 (0) 3 710 53 01
- Brazil**, Bio-Rad Laboratories Brasil Ltda, Avenida Doutor Clucri Zaidan, 1.240 cj 1902 e 1904 Morumbi Corporate Santo Amaro, São Paulo, SP CEP 04711-130 • Phone +55 11 3065 7550
- Canada**, Bio-Rad Laboratories Ltd., 2403 Guénette Street, Montréal, Québec H4R 2E9 • Phone +1 514 334 4372 • Fax +1 514 334 0872
- China**, Bio-Rad Laboratories (Shanghai) Co., Ltd. Room 601, Allian Plaza, No. 168 Jingzhou Road, Yangpu District, Shanghai 200082 • Phone +86 21 6169 8500 • Fax +86 21 6169 8599
- Czech Republic**, Bio-Rad spol. s r.o., Piktova 1737/1a, 14000 Prague 4 • Phone +420 241 431 660
- Denmark**, Bio-Rad Laboratories, Symbion Science Park, Fruebjergvej 3, DK-2100 Copenhagen East • Phone +45 44 52 10 00 • Fax +45 44 52 10 01
- Finland**, Bio-Rad Finland Oy, Kutomotie 16 FI-00380, Helsinki • Phone +358 9 804 22 00
- France**, Bio-Rad, 3 boulevard Raymond Poincaré, 92430 Marnes-la-Coquette • Phone +33 (0) 1 47 95 60 00 • Fax +33 (0) 1 47 41 91 33
- Germany**, Bio-Rad Laboratories GmbH, Kapellenstraße 12, D-85622 Feldkirchen, Munich • Phone +49 (0) 89 31884 393 • Fax +49 (0) 89 31884 136
- Greece**, Bio-Rad Laboratories M.E.P.E. 2-4 Mesogion Ave. (Athens Tower) 11527 Ampelokipi, Athens • Phone +30 210 7774396 • Fax +30 210 7774376
- Hong Kong**, Bio-Rad Pacific Ltd., Unit 1101, 11/F DCH Commercial Centre, 25 Westlands Road, Quarry Bay • Phone +85 2 2789 3300 • Fax +85 2 2789 1257
- Hungary**, Bio-Rad Hungary Ltd., Futó utca 47-53, 1082, Budapest • Phone +36 1 459 6190 • Fax +36 1 459 6101
- India**, Bio-Rad Laboratories India Pvt. Ltd., EMAAR Digital Greens, 9th Floor, Tower A- Sector 61 Gurugram-122 102, Haryana 122 015 • Phone +91 124 4029300 • Fax +91 124 2398115
- Israel**, Bio-Rad Laboratories Ltd., 14 Homa Street, New Industrial Area, Rishon Le Zion 75150 • Phone +972 3 963 6025 • Fax +972 3 951 4129
- Italy**, Bio-Rad Laboratories S.r.l., Via Cellini 18/A, 20090 Segrate, Milan • Phone +39 02 94 86 600 • Fax +39 02 21609399
- Japan**, Bio-Rad Laboratories K.K., Tennoz Central Tower 20F, 2-2-24 Higashi-Shinagawa, Shinagawa-ku, Tokyo 140-0002 • Phone +81 3 6361 7070 • Fax +81 3 5463 8481
- Korea**, Bio-Rad Korea Ltd., 10th Floor, Hyunjuk Building, 832-41, Yeoksam-dong, Gangnam-gu, Seoul 135-080 • Phone +82 080 007 7373 • Fax +82 (2) 3472 7003
- Mexico**, Bio-Rad S.A., Avenida Eugenia 197, Piso 10-A, Colonia Narvarte, Delegación Benito Juárez C.P. 03020 Mexico, D.F. • Phone +52 (55) 5488 7670 • Fax +52 (55) 1107 7246
- The Netherlands**, Bio-Rad Laboratories B.V., Postbus 222, 3900 AE Veenendaal • Phone +31 (0) 318 540 666 • Fax +31 (0) 318 542 216
- New Zealand**, Bio-Rad New Zealand, 189 Bush Road Rosedale, Auckland • Phone +64 (9) 415 2280 • Fax +64 (9) 415 2284
- Norway**, Bio-Rad Laboratories, Nydalsveien 33, 0484 Oslo • Phone +47 23 38 41 30 • Fax +47 23 38 41 39
- Poland**, Bio-Rad Polska Sp. z o.o., Przyokopowa 33, Level 4, Building A, 01-208, Warsaw • Phone +48 22 331 99 99 • Fax +48 22 331 99 89
- Portugal**, Bio-Rad Laboratories, Lda., Edifício Prime, Ave. Quinta Grande, 53 - Fracção 3B Alfragide 26114-521, Amadora • Phone +351 21 47 27 700 • Fax +351 21 47 27 777
- Russia**, Bio-Rad Laboratorii, 5 Nizhny Susalny Lane, Property 5A, Moscow • Phone +7 (495) 721-14-04 • Fax +7 (495) 721-14-12
- Singapore**, Bio-Rad Laboratories (Singapore) Pte. Ltd., 3A International Business Park Road, #11-10/16, ICON @ IBP Tower B, Singapore 609935 • Phone +65 6415 3170 • Fax +65 6415 3189
- South Africa**, Bio-Rad Laboratories (Pty) Ltd., 34 Bolton Ave, Rosebank, Johannesburg • Phone +27 11 442 8508 • Fax +27 11 442 8525
- Spain**, Bio-Rad Laboratories, S.A., C/ Caléndula, 95, Edificio M. Miniparc II, El Soto de la Moraleja, 28109 Alcobendas • Phone +34 91 490 6580 • Fax +34 91 590 5211
- Sweden**, Bio-Rad Laboratories A.B., Solna Strandväg 3, SE-171 54 Solna, P.O. Box 1097, SE-172 22 Sundbyberg • Phone +46 844 98053 • Fax +46 8 55 51 27 80
- Switzerland**, Bio-Rad Laboratories AG, Pra Rond 23, CH-1785 Cressier • Phone +41 (0) 61 717 9555 • Fax +41 (0) 61 717 9550
- Taiwan**, Bio-Rad Laboratories Taiwan Ltd., 14th F B, No. 126, Sec. 4, Nan-King East Road, Taipei 10546 Taiwan, R.O.C. • Phone +886 (2) 2578-7189 • Fax +886 (2) 2578-6890
- Thailand**, Bio-Rad Laboratories Ltd., 1st & 2nd Floor, Lumpini Bldg., 239/2 Rajdamri Road, Lumpini, Pathumwan, Bangkok 10330 • Phone (662) 651 8311 • Fax (662) 651 8312
- United Kingdom**, Bio-Rad Laboratories Ltd., The Junction Station Road, Watford, Hertfordshire, WD17 1ET • Phone +44 (0) 1923 471301 • Fax +44 (0) 1923 471340

BIO-RAD Lyphochek® Assayed Chemistry Control, Levels 1 and 2

INSTRUMENT (1)

	Units	Level 1 - 26491		Level 2 - 26492	
		Mean	Range	Mean	Range
BIOSYSTEMS B400/A25/A15 (5) (continued)					
Urea (Urease, UV) (4)	mg/dL	29.9	25.4 – 34.4	91.0	77.4 – 105
Uric Acid (Uricase, colorimetric)	mg/dL	4.91	4.17 – 5.65	8.58	7.29 – 9.87
ERBA XL SERIES (5)					
Albumin	g/dL	3.90	3.30 – 4.50	2.70	2.28 – 3.12
Albumin (India Market Only)	g/dL	3.96	3.36 – 4.56	2.69	2.30 – 3.08
Alkaline Phosphatase (IFCC Optimized) (2)	U/L	115	92.1 – 138	487	391 – 583
Alkaline Phosphatase (India Market Only) (2)	U/L	115	91.0 – 139	476	380 – 572
ALT/SGPT (2)	U/L	27.6	22.2 – 33.0	104	83.5 – 125
ALT/SGPT (Modified IFCC) (India Market Only) (2)	U/L	27.4	22.0 – 32.8	102	81.0 – 122
Amylase (2)	U/L	60.5	48.5 – 72.5	393	315 – 471
AST/SGOT (2)	U/L	38.2	30.7 – 45.7	204	162 – 246
AST/SGOT (Modified IFCC) (India Market Only) (2)	U/L	37.1	29.6 – 44.6	199	160 – 238
Bilirubin (Direct)	mg/dL	0.370	0.280 – 0.460	1.31	0.980 – 1.64
Bilirubin (Direct) (DCA)	mg/dL	0.390	0.300 – 0.480	1.65	1.23 – 2.07
Bilirubin (Total)	mg/dL	0.990	0.750 – 1.23	4.77	3.57 – 5.97
Bilirubin (Total) (DCA)	mg/dL	1.01	0.770 – 1.25	4.70	3.53 – 5.87
Calcium	mg/dL	9.94	8.44 – 11.4	13.4	11.3 – 15.5
Calcium (India Market Only)	mg/dL	9.21	7.83 – 10.6	12.3	10.5 – 14.1
Carbon Dioxide (CO2)	mEq/L	34.5	27.6 – 41.4	19.0	15.2 – 22.8
Chloride	mEq/L	107	96.0 – 118	93.0	83.7 – 102
Chloride (Mercuric Thiocyanate)	mEq/L	109	94.0 – 124	101	86.0 – 116
Cholesterol (HDL) (7)	mg/dL	67.2	53.7 – 80.7	23.9	19.1 – 28.7
Cholesterol (LDL)	mg/dL	149	119 – 179	67.6	54.1 – 81.1
Cholesterol (Total)	mg/dL	251	212 – 290	104	88.0 – 119
Cholinesterase (2)	U/L	7492	5995 – 8989	1131	906 – 1356
Creatine Kinase (CK) (2)	U/L	141	114 – 168	463	370 – 556
Creatinine (Alkaline picrate method)	mg/dL	2.59	2.08 – 3.10	5.74	4.60 – 6.88
Creatinine (Enzymatic)	mg/dL	1.80	1.44 – 2.16	5.21	4.16 – 6.26
Creatinine (Enzymatic) (India Market Only)	mg/dL	1.66	1.33 – 1.99	4.80	3.90 – 5.70
Gamma Glutamyltransferase (GGT) (2)	U/L	66.3	53.1 – 79.5	167	134 – 200
Glucose	mg/dL	91.7	77.9 – 106	304	259 – 349
Glucose (Hexokinase) (India Market Only)	mg/dL	85.4	72.5 – 98.3	285	243 – 327
Iron	µg/dL	236	188 – 284	62.1	49.8 – 74.4
Iron (UIBC)	µg/dL	63.3	50.7 – 75.9	126	102 – 150
Lactate Dehydrogenase (LDH) (2)	U/L	333	267 – 399	888	711 – 1065
Lipase (2)	U/L	43.1	34.4 – 51.8	57.7	46.3 – 69.1
Lithium	mEq/L	0.460	0.400 – 0.520	1.71	1.53 – 1.89
Magnesium	mg/dL	1.91	1.61 – 2.21	4.49	3.83 – 5.15
Phosphorus (India Market Only)	mg/dL	3.87	3.30 – 4.44	7.20	6.00 – 8.40
Phosphorus (New Formulation)	mg/dL	3.91	3.31 – 4.51	7.74	6.57 – 8.91
Potassium	mEq/L	3.61	3.25 – 3.97	5.49	4.95 – 6.03
Protein Serum (Total)	g/dL	6.94	5.89 – 7.99	4.75	4.03 – 5.47
Protein Serum (Total) (India Market Only)	g/dL	6.51	5.52 – 7.50	4.30	3.70 – 4.90
Sodium	mEq/L	140	126 – 154	123	110 – 135
Triglycerides	mg/dL	186	159 – 213	96.1	81.7 – 111
Triglycerides (India Market Only)	mg/dL	182	155 – 209	82.6	70.3 – 94.9
Urea (4)	mg/dL	33.8	28.7 – 38.9	103	88.0 – 118
Uric Acid	mg/dL	5.38	4.57 – 6.19	10.8	9.30 – 12.3



HEALTH HORIZON DIAGNOSTICS

DEFICIENCIES RESPONSE SHEET

FOR LDL-CHOLESTEROL



DEFICIENCIES RESPONSE SHEET

HEALTH HORIZON DIAGNOSTICS

Page 1 of 1

OBSERVATION:

NO PT EVIDENCED FOR LDL-CHOL.

RESPONSE:

As per the query raised for the test LDL , we wanted to correct the method for LDL test which is used in our laboratory is calculated and not by Direct method. Kindly accept this method and guide us regarding the same.

RECORDED BY:
Technical Manager

Shameer
08/04/2023

REVIEWED BY:
Lab Head/Quality Manager

Akash
08/04/2023